



Universiteit
Leiden
The Netherlands

Blood and Biomarkers in Huntington's Disease

Mastrokolas, A.

Citation

Mastrokolas, A. (2017, September 7). *Blood and Biomarkers in Huntington's Disease*. Retrieved from <https://hdl.handle.net/1887/54854>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/54854>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/54854> holds various files of this Leiden University dissertation.


Author: Mastrokolias, A.

Title: Blood and Biomarkers in Huntington's Disease

Issue Date: 2017-09-07

Chapter 1

General Introduction



1.1 Huntington's Disease

1.1.1 Huntington's disease discovery and epidemiology

Huntington's disease is an autosomal dominant neurodegenerative disease that manifests through motor and psychiatric symptoms. Huntington's disease was first described and named after George Huntington in 1872; who in his paper "On Chorea" described the major aspects of the disease [1]. However, it was not until 1983 when the disease was first mapped to a restriction fragment length polymorphism marker (RFLP) (D4S10/G8) [2] on chromosome 4 and it took 10 years more (1993) before it was linked to "interesting transcript 15" (IT15) following which the HD gene was identified and isolated [3]. Since current knowledge about the human genome was unavailable at the time, the long search for the identification of the disease gene was further limited by the telomeric location of the RFLP marker, the physical distance as well as uncertain recombination frequencies between the marker and the disease locus [4,5]. HD population prevalence exhibits significant geographic differences depending on local, past migration patterns and ethnicity. The disease is most prominent in Western European populations with a rate of occurrence of 5-10 in 100.000, a prevalence of approximately 1 in 10.000 in Caucasian populations [6,7] and is least frequent in Japanese, Chinese, Finnish and African descent individuals [8]. However, as suggested by Evans et al., the disease prevalence has risen significantly in the last decades and it was found that for UK the number of HD patients was 12.3 per 100.000 [9]. Localized geographic areas exhibit very low as well as very high prevalence with the most notable example being the population of Lake Maracaibo in Venezuela which was also originally used to identify the disease gene [10].

1.1.2 Huntington's disease genetics

Huntington's disease is caused by an expanded CAG repeat in the HTT gene. Individuals that carry a CAG repeat higher than 35 are the ones that will most likely develop the disease symptoms at some point during their lifetime [11]. People with 36-39 repeats are known to carry a reduced penetrance allele and they may develop the disease rather later in life (40% chance asymptomatic at age 65) [12]. For most mutation carriers disease

onset takes place between 35 and 50 years old [13]. However, symptom onset can occur at any time during the carrier's lifetime and is inversely correlated to the CAG expansion length. As a result, people with 40 repeats or more will develop the disease and when the repeat exceeds 50 symptoms may develop as early as childhood. The elongated CAG tract results in a mutant huntingtin protein with an elongated polyglutamine tract that is associated with protein aggregation and toxic gain-of-function properties [14]. During meiotic transmission, the HD repeat is unstable in more than 80 % of the cases (increases and decreases) while the largest increases are seen in paternal transmissions [15]. This meiotic instability leads to genetic anticipation of the disorder (increasing intergenerational disease severity) but also to the generation of de-novo HD mutation carriers from unaffected parents; especially from parents which exhibited an increased glutamine repeat number and within the intermediate repeat area of the disease (27-35 CAGs) [16,17]. Nevertheless, the HD gene mutation only explains about 50-77 % of the variance in the age of symptom onset and scientists are continuously looking for genetic as well as environmental modifiers of disease onset [18,19]. Several genetic modifiers have been identified that further influence the trinucleotide repeats instability as well as the age of onset of the disease. Such genetic modifiers influence the manifestation of disease phenotypes and partially explain the variability and degree to which these symptoms develop [18,20,21]. Apart from genetic modifiers, there are also specific factors that lead to the unstable transmission of the, disease causing, trinucleotide repeat expansion and include toxic oxidation which is known to cause progressive age-dependent expansions [22,23] as well as population specific haplotypes made up of sets of single nucleotide polymorphisms [24]. On the other hand, genetic modifiers that influence the disease onset include functional polymorphisms in key genes involved in neuronal processes, the processing of huntingtin itself, gene transcription but also metabolism. Examples of affected genes include the a) kainate receptor *GluR6* [25] b) glutamate receptor, ionotropic, N-methyl-d-aspartate – *GRIN2A/2B* [26] c) gene transcription factor *TP53* [27] d) the Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha (*PPARGC1A*) transcription factor that is involved in regulating energy metabolism genes [28,29]. Finally, in a recent very large genome wide association study two different chromosomal loci were discovered (chromosomes 8 and 15) that exhibited independent effects of disease onset acceleration and/or delay [30]. The functional variants within

the above two chromosomal loci are thought to affect genes involved in DNA synthesis and repair, mitochondrial energetics and oxidative stress (*FAN1*, *MTMR10*, *RRM2B*, *UBR5*). The presence of all the above genetic differences in HD mutation carriers shows that detailed genotypic information will be required in order to efficiently address the manifested disease symptom variability.

1.1.3 Huntington's disease motor symptoms

One of the most prominent features of HD is the movement disorder known as chorea [31]. Chorea is characterized by hyperkinetic dance like movements and ranges from random, exaggerated gestures and expressions to continuous and violent movements. Huntington's disease patients are also characterized by non-choreatic, hypokinetic movements such as bradykinesia and dystonia. Hypokinetic movements are usually more prominent during middle and late stages of the disease while, on the other hand, hyperkinetic movements are usually present at early to middle stages of the disease. Specifically, as the functional capacity of patients declines, the presence of chorea lessens and the presence of dystonia is intensified [32]. Additional motor symptoms include the slowness of movements (bradykinesia), rigidity and clumsiness. Aside from choreatic or dystonic motor symptoms patients also exhibit skeletal muscle wasting and weight loss (see 1.2.4) [33]. The above two observations take place irrespective of the fact that HD patients receive a steady caloric intake [34]. HD patients further exhibit ocular abnormalities such as the inability to suppress reflexive saccades to a new optical stimulus, and are characterized by delayed initiation of voluntary saccades (reflexive and voluntary eye control respectively) [35]. These ocular dysfunctions can be in turn linked to potentially affected brain areas since it has been shown that saccadic eye movement control is partially controlled by the hippocampus, the inferior parietal lobule and the prefrontal cortex [36,37]. Finally, in subsequent and more advanced stages of the disease the patients are exhibiting dysarthria (speech problems), dysphagia (swallowing difficulties) and balance disturbances, with the latter two problems constituting potential death causes by aspiration pneumonia or serious injury respectively [38-41].

1.1.4 Huntington's disease cognitive and psychiatric symptoms

HD is characterized by cognitive and psychiatric symptoms such as depression, irritability, apathy, anxiety and dementia. The above symptoms are usually evident well before the onset of any motor symptoms and get significantly worse over time. Nevertheless, psychiatric symptoms do not always correlate with cognitive and motor aspects of the disease and specific symptoms are sometimes more highly associated with certain disease stages, such as the manifestation of depression at the same time or after onset of motor symptoms [42,43]. Previous studies have identified that depression is a significant component of the prognostic signature of HD and that such affective disorders can appear as early as 20 years before choreatic and cognitive symptom onset [44]. Another study of depression in HD has reported that over 40 % percent of HD patients had significant symptoms of depression and over 50 % had previously received treatment for depression [45]. These numbers are significantly higher than the prevalence of depression in the general population (8-12 %) [46]. The exact reason behind the high number of reports of depression in HD is not clear. However, it has been hypothesized that apart from potential perturbed biological pathways this could be also due to the adjustment of these patients to the idea that they suffer from a disabling, terminally ill disorder [47,48]. Moreover, anxiety and irritability have also been reported in HD at a prevalence varying from 34-61% and 38-73% respectively [49] which is also much higher than the reported lifetime prevalence of any other anxiety disorder as reported from the World Mental Health surveys[50]. HD patients are likewise often characterized by apathy and specifically reduced energy and lack of drive. It has been proposed that in HD and other neuropsychiatric diseases, apathy is distinct from depression and associated with disinhibition and aberrant motor behavior, in contrast to anxiety and irritability which characterize depression [51]. Finally, obsessive and compulsive symptoms as well as psychotic symptoms have also been reported in HD mutation carriers, even though at a much lower prevalence (10-52 % and 3-11% respectively) [43,49].

1.2 Huntington's disease neuropathology

Huntington's disease is characterized by atrophy of the cerebral cortex and the striatum

and HD patients are known to lose up to 40% of their brain volume compared to healthy individuals [52,53]. Neurodegeneration affects mostly the medium spiny projection neurons of the striatum while the interneurons are relatively spared [54]. The neurodegeneration mechanism of the mutant huntingtin protein however appears to be complex and neuronal death does not always correlate to huntingtin nuclear inclusions [55]. One of the most used methods to classify HD neuropathological severity is the Vonsattel ascending severity order grading system (Grades 0-4) that was formulated using post-mortem brain specimens in order to identify the microscopic and macroscopic changes taking place in mutation carrier brain tissue [56]. Vonsattel et al. reported a caudate nucleus neuronal loss of 50-95% from grades 1-4 and a big increase of astrocytic population during grades 2-4. The authors also reported that the earliest changes were found in the medial paraventricular areas of the caudate nucleus and dorsal part of the putamen as well as the fact that anatomical changes were usually lagging behind the clinical symptoms something that has also been confirmed by later studies [57,58]. Apart from the neuronal degeneration pattern that is evident in the striatum of HD patients, other areas are affected too such as the substantia nigra, globus pallidus, thalamus and cerebellum [59]. The multiplicity and the variable degree of degeneration of the affected brain areas constitute the basis for the diverse clinical phenotype and disease progression rates the patients exhibit. The latter assumption has been supported by imaging studies, which have revealed a widespread brain tissue degeneration and significant volume reductions in almost all brain areas; occurring even in early stage patients [60-63].

1.2.1 Huntingtin protein structure and function

Wild type Huntingtin (Htt) protein is 348 kDa, expressed ubiquitously and its highest levels are found in the brain and the testis [3,64-66]. The exact 3D and molecular structure of the protein has not been yet achieved due to the high molecular weight of the protein and the problems this causes in X-ray crystallography. Currently, in an ongoing attempt to identify its protein structure huntingtin has been transferred to the international space station in an effort to take advantage of extraterrestrial weightlessness condition and microgravity crystallization techniques (NASA mission experiment CASIS PCG HDPCG-1). Structurally, the HD protein is characterized by a CAG repeat and

by a proline rich domain which are located in the protein N terminus [3]. The presence of similar homopolymeric glutamine and proline stretches in many transcription factors has lead scientists to the conclusion that huntingtin is also one such protein with similar functional properties [67-69]. Apart from its distinctive N-terminal structure the protein possesses several well described consensus motifs that are required for many protein-protein interactions – which is another characteristic of Htt [70]. Such patterns, sequences or motifs include: a) Huntingtin, elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the yeast kinase TOR1 - (HEAT) - repeats [71] b) proteolytic cleavage sites that allow the fragmentation of the protein through the function of caspases 2,3,6 and 7 [72,73] c) nuclear localization sequences [74] and d) posttranslational modification sites such as those for its phosphorylation and ubiquitination [75-78]. The wild type protein was initially considered to be found only in the cytoplasm and associated with the Golgi apparatus, the microtubules and the endoplasmic reticulum [79-81]. However, an early study by Hoogeveen et al. and later one by De Rooij et al. showed that huntingtin was also present in the nucleus [82,83]. This discovery further emphasized important protein roles such as transcriptional control, a role supported by the structural features and motifs that Htt possesses, like poluglutamine stretches and leucine zipper motifs. Huntingtin is also found in clathrin coated vesicles and it has been proposed that it interacts with proteins involved in cytoskeletal transport, receptor mediated endocytosis as well synaptic recycling [84,85]. Even though the highest huntingtin levels are found in the central nervous systems [86-88] the exact function of the wild type protein is still not completely understood. Nonetheless early research in the field into the function of the protein has shown that huntingtin is required during gastrulation in early embryogenesis and has a vital role in the functioning of the basal ganglia and neuronal survival [89,90]. Additionally, further studies have demonstrated that huntingtin may possess many further roles in many key cellular pathways. Several roles have been proposed for huntingtin: possessing an anti-apoptotic role and protecting from excitotoxicity [91,92], regulating the production of neurotrophic factors such as brain derived neurotrophic factor (BDNF) [93,94], participating in or disrupting axonal transport and vesicle trafficking [95,96] and regulating synaptic function through partner proteins such as PSD-95 [97,98].

1.2.2 Mutant huntingtin aggregates and inclusions

Soon after the discovery of the HD causal mutation the presence of neuronal aggregates and inclusions of mutant huntingtin was also established as one of the main disease pathological hallmarks. The designation of the aggregates as the main disease hallmark was made possible through a series of successful experiments that used mouse and human studies to initially locate neuronal intranuclear inclusions and dystrophic neurites in HD brain [99] and later identify their role in toxicity, or protection therefrom, and in disease neurological phenotypes [100,101]. Even though the mechanisms through which Htt inclusions or Htt fragment inclusions lead to toxicity and neurodegeneration have not been completely elucidated. Some of the hypotheses advanced include interference and sequestration of essential cellular proteins and transcription factors, proteasomal component interference and functional impairment [102,103], apoptosis [104], mitochondrial function damage [104,105] and alterations in cytoskeletal and synaptic function [106]. The factors that determine the capacity of the mutant Htt to aggregate include the length of the polyglutamine expansion and the length of huntingtin polyglutamine fragments [107], the specific conformation of the mutant protein as well as the sequences that flank the polyglutamine stretch such as the poly-proline motif located downstream of the CAGs [108]. Miller et al. have suggested that the rate-limiting step for the formation of inclusion bodies (nuclear or cytoplasmic aggregates) are the different conformational changes in monomeric Htt exon 1 fragments [109]. This suggests that only modest reductions in the levels of the mutant proteins or even their relative conformation ratios can have a profound effect in aggregate formation and toxicity [109,110]. Another significant factor correlated with the increased aggregate formation is the mutant protein proteolytic cleavage and the subsequent formation of N-terminal fragments. Specifically, the function of proteases such as caspase and calpain have been shown to increase the formation of aggregates and neuronal susceptibility to cell death [111-113]. Independently of all the above factors influencing aggregate formation, the propensity of the mutant huntingtin to aggregate and cause disease pathology could additionally depend on chaperones [114,115], posttranslational modification enzymes [116,117] and can be influenced by the specific neuronal cell type properties and the mutant huntingtin expression levels and dynamics in particular cell types such as primary

neurons, astrocytes, oligodendrocytes and microglia [118-120].

1.2.3 Huntington's disease brain pathology

Postmortem examinations of HD carriers have shown that the brain tissue changes are mostly evident in advanced stages [121] and are characterized by tissue losses in the cerebral cortex and thalamus (reductions 21-29%) as well as the caudate and putamen (57% and 64% tissue loss respectively). Even though these large tissue losses are more visible in later disease stages, recent studies have shown that such brain atrophy and white matter disorganization events can even take place before the onset of disease clinical symptoms [122]. For example, medium spiny neurons make up to 95% of the striatal neuronal cell population and contain a plethora of metabotropic, glutamate and dopamine receptors [123,124]. These receptors have been the subject of intense research as to the possible mechanisms through which they can cause or contribute to neuronal cell death (see 1.3.4). In the majority of HD cases the binding capacities of these receptors is reduced and this capacity reduction has been correlated to neuronal cell death [125,126]. Nonetheless it is not completely clear yet if this receptor dysfunction leads to cell death or vice versa [126]. On the other hand, some cell types such as the striatal interneurons, the medium-sized calretinin-positive interneurons and the neuropeptide Y/somatostatin containing neurons are relatively spared, even in more advanced disease stages [127]. The reason that these cell types are less susceptible to the disease is not yet fully understood. It has been postulated however that this preservation can be related to the distribution of the cells in the corresponding brain areas as well as their relative position to excitatory neuroreceptors responsible for cell over-excitation and subsequent cell death [128]. Finally, it has been shown that the cellular and neurochemical changes that take place in HD patient brains are accompanied by gliosis [129-131]. Gliosis is characterized as an increase in the population as well as the activation of astrocytes, microglia and oligodendrocytes [128]. Microglial activation has been found widespread through the cortex, the pallidum and striatum and it has been even found to be present in pre-symptomatic carriers [132,133].

1.2.4 Huntington's disease peripheral pathology

Even though Huntington's disease has been traditionally considered as a brain disorder it is characterized by additional peripheral symptoms such as weight loss and skeletal muscle wasting, glucose intolerance, heart and gastrointestinal problems as well as testicular atrophy [134-138]. An increasing number of studies points to the fact that these peripheral symptoms are not solely or even partially due to neurodegeneration of brain cell structures and brain factors but are a result of the mutant protein expression in the specific peripheral tissue cells and occur in parallel with the central nervous system [107,139]. Notably intracellular mutant protein inclusions as well as peripheral skeletal muscle cell dysfunction have been shown to be present even when the peripheral cell types are isolated [140,141]. Weight loss is one of the most common symptoms and especially in symptomatic HD individuals. Several studies have indicated that this weight loss is not only associated with nervous system damage but is also a result of an increased metabolic rate in these patients [142,143]. Moreover, it has also been shown that weight loss does not always follow symptom onset and a multifactorial system could govern the start of weight changes in symptomatic and pre-symptomatic patients [136]. Furthermore according to a different study skeletal muscle wasting can also be attributed to expression of the mutant huntingtin protein in the myocytes and a transition from slow-twitch to fast-twitch muscle fibers [144]. In addition, and using mouse models, it was shown that mutant huntingtin affects gene expression patterns in myocytes and that these expression changes are in parallel with early pathological and behavioral changes [144,145]. Other human as well as mouse studies have shown that HD mutation carriers are more likely to develop osteoporosis, diabetes, pancreatic dysfunction and impaired glucose tolerance [146-148]. Finally, the role of the immune system has been the focus of several studies and it has been shown that in HD blood is characterized by increased concentrations of proinflammatory and chemotactic cytokines such as interleukins 6 and 8, altered inflammatory signaling and a general overactivation [149-151]. This deregulation of the immune system has been attributed to expression of the mutant Htt protein in the immune system cell types affecting cell signaling and cytokine release and migration [152]. Most importantly such an immune system over activation does not have an isolated cell type effect but appears to influence other prominent peripheral degeneration events described

above such as muscle wasting and gene expression deregulation [153,154].

1.3 Huntington's disease mechanisms of cytotoxicity

Even though HD is a monogenic disorder the disease pathology is very multifaceted. The cytotoxic function of the aggregated mutant Htt protein can exert its effect through a plethora of processes as described above (see 1.2.2). In addition, it has been shown that mutant huntingtin cleavage products (especially N-terminal fragments) exacerbate the disease pathology. They are more toxic than full length huntingtin and increase the number of intranuclear inclusions [55,155]. Huntingtin is proteolytically cleaved by caspases like caspase 3 and 6 and it has been shown that inhibiting caspase activity can reduce toxicity and aggregate formation (see 1.4.5). It has been proposed that increased caspase activation and substrate cleavage, caused in HD by intranuclear Htt accumulation and release of mitochondrial cytochrome c [156], can also be the cause behind phenotypic similarities across other neurodegenerative diseases such as Alzheimer's disease [55,157,158]. In the following paragraphs, previously mentioned and additional mechanisms of cytotoxicity are described in more detail.

1.3.1 Proteasomal deregulation

The ubiquitin-proteasomal system is one of the main mechanisms of cellular protein degradation in the nervous system and is involved in processes such as neuronal transmission and neuronal plasticity [159]. In HD, it has been shown both in humans and animal models that the mutant huntingtin protein is targeted for proteolysis but is resistant to its processing [99]. Studies that used HTT exon1 transfection polyglutamine aggregates labelled with antibodies against parts of the ubiquitin-proteasomal system demonstrated co-localization with the protein inclusions as well as altered localization that could potentially adversely affect the proteasomal system function [160]. The reduced proteasomal ability to cleave the mutant protein as well as other polyglutamine proteins is attributed to the greatly expanded length of glutamine repeats of the mutant protein. As a result, these proteins are getting "stuck" in the 20S subunit of the proteasome and do not allow for the subsequent entry of the remaining catalytic substrates and other

proteins [161]. Additionally, using fluorescence recovery after photo-bleaching (FRAP) optical technology it was shown that the proteasome was irreversibly trapped within the N-terminal mutant huntingtin aggregates both in vivo and in vitro [162]. Even though the results of the previous study did not exclude the possibility of partial proteasome activity or Htt partial degradation – over time this delay in huntingtin or other substrate processing could have deleterious and adverse effects for cellular viability. Moreover, it should be noted that the results concerning the inability of the proteasomal system to degrade the mutant expanded proteins are often contradictory. For example, and in contrast to previous studies, Rousseau et al. have suggested that the aggregation is not a result of the main 20 S proteasomal subunit failure but rather of 19S regulatory particles (Rpt4/Rpt6) flanking the proteasomal catalytic core [163]. Additional data that further diffuse the role of proteasomal dysfunction in HD have shown that it is only the filamentous mutant Htt aggregates that have the potential to inhibit proteasomal function and not the formation of inclusion bodies (IBs) [164]. Despite of the opposing study results described above about the role of proteasome in HD, this proteolytic complex constitutes a very interesting therapeutic target since even if its function is shown not to be affected its activity may be targeted for additional stimulation and enhanced clearance of the polyglutamine fragments [165].

1.3.2 Transcriptional deregulation

The wild type huntingtin protein has also been shown to have a role in transcription regulation and to interact with many other transcription factors and regulatory proteins [166]. On the other hand, during disease it has been confirmed that Htt mutant protein and protein fragment aggregates are involved in the sequestration of proteins involved in transcription, irregular subcellular localization of CAG containing transcripts, alternative splicing; all events that lead to genome wide transcriptional deregulation in HD patients [167]. Specifically, it has been established that important cellular transcription factors such as TATA binding protein, CBP, SP1 and p53 are recruited to these aggregates [168-170]. In two such studies it was shown that Sp1, a well-known wild type Htt interactor, exhibits reduced DNA binding (caused by mutant Htt) and that genes regulated by Sp1 exhibited decreased expression [145,171]. Gene expression microarray

studies in human and animal models have shown that the functional types of those genes whose expression is affected by mutant huntingtin include neuronal structure genes, signaling receptors, axonal receptors and stress response genes [172,173]. In a recent study by Labadorf et al. it was also shown that HD brain deregulated genes were enriched for immune response and neuroinflammatory genes as well as homeotic genes (Hox – Homeobox genes) – a set of genes that has not yet been widely investigated in the light of HD [174]. Furthermore, it has been suggested that these mRNA changes were not attributable to cell loss only and exhibited a distinct disease related brain regional pattern, with gene expression similarities between those expressed in the HD caudate and the motor cortex [175]. Other important factors and regulators that have been implicated in HD transcriptional deregulation and whose function is influenced by the mutant protein include the neuronal factor transcriptional repressor *REST* [176], the peroxisome proliferator-activated receptor gamma (*PPARγ*) [177] and the heat shock protein transcription regulator *NF-Y* [178].

Another major transcriptional mechanism disrupted in HD, which has potentially even greater influence than individual transcriptional factors deregulation, is chromatin remodeling. Chromatin remodeling is regulated by epigenetic processes such as histone posttranslational modifications and DNA methylation [179]. Studies from HD models have reported that mutant huntingtin also interferes with the function of enzymes involved in chromatin remodeling such as histone acetyltransferases, histone methyltransferase, ubiquitin ligases and transglutaminases [180]. Specifically, it has been shown that inhibition of histone deacetylases by inhibitors such as sodium butyrate and phenylbutyrate reversed the mutant protein related neurodegeneration [181,182]. Histone methylation is an epigenetic mechanism used to activate or repress transcription however it has been demonstrated that in HD histone methylation related proteins such as ERG-associated protein with SET domain (ESET) and its activator Sp1 are also deregulated in HD [183]. Post-translational modifications as the ones performed by transglutaminases have also been shown to exhibit increased activity while their inhibition with cystamine in HD models ameliorated symptoms and increased the expression of neuroprotective genes [184]. Much attention has been given lately to the role of miRNAs in HD and their gene expression regulatory roles like for miR-9 and the neuronal gene expression RE1-Si-

lencing Transcription Factor (REST) [185,186]. Finally, other ways in which chromatin remodeling is affected in HD and normal function of the histone core proteins is disrupted are monoubiquitilation and post-translation modifications such as phosphorylation of serine, threonine and tyrosine residues [172,187].

1.3.3 Mitochondrial activity and energy metabolism deregulation

Mitochondria are well known regulators of cellular health and are involved in cellular energy production, metabolism as well as apoptosis [188]. The mitochondria are another cellular compartment that is thought to be disrupted in HD and eventually also contributing to neuronal cell death. A lot of studies both in animal models and humans have described many different aspects of mitochondrial dysfunction in HD. The different mechanisms of HD mitochondrial dysfunction can be briefly categorized into : a) mitochondrial membrane destabilization b) reduction of the mobility of the mitochondria c) reactive oxygen species (ROS) overproduction with a concomitant Ca^{2+} cellular vulnerability through the deregulation of the mitochondrial permeability pore [105]. More specifically, studies have shown that HD mitochondria exhibit increased CAG repeat length correlated membrane depolarization [189], reduced membrane potential requiring lower calcium depolarization loads [190] and reduced Ca^{2+} loading capacity as well as evidence that Ca^{2+} dependent pathways lead to oxidative phosphorylation impairment of HD mitochondria [191]. It has been demonstrated that full length mutant Htt blocks mitochondrial movement and this effect correlates with increased mutant protein expression in the cytosol [192]. The same study showed that the mitochondria accumulated in areas of aggregates while their trafficking was unchanged at neuronal areas that lacked aggregates. Reactive oxygen species, produced by the mitochondria during oxidative phosphorylation, have shown to be increased in HD. This has been attributed to the presence of the mutant protein [193] and microglial over-activation which typically occurs after brain injury or immunological stimuli and has been shown to correlate with disease severity [194,195]. Moreover it has been shown that dysfunctional mitochondrial metabolism in HD patients leads to diminished complex II, III and IV activity in the caudate nucleus [196], decreased glucose metabolism and inhibition

of the metabolic regulator and transcriptional coactivator PGC-1alpha [197-199], as well as increased lactate production in the cortex and the basal ganglia [200,201]. Finally, the deregulation of neurotransmitters such as dopamine and glutamate present at the striatum and their disordered interactions with the mitochondrial system could also account for the preferential vulnerability of these brain areas to the mutant Htt protein which involves but is not limited to processes such as the reduction of cellular ATP stores, deregulation of intracellular Ca²⁺ levels, increased synaptic dopamine levels and impaired glutamate uptake due to increased production of ROS [202,203].

Despite the fact that so many studies have provided important clues about the deregulation of individual genes and complexes of mitochondrial metabolism it is still unclear to what extent these mitochondrial defects have a causal effect in the disease or if they are just the result of long term disease toxicity [204]. Finally, for any one of the aforementioned genes or molecules to be targeted in therapeutic approaches e.g. to equilibrate their levels, their role in energetic pathways, and their interactors, have to be extensively investigated to avoid unwanted non-specific detrimental effects.

1.3.4 Synaptic dysfunction and excitotoxicity

Several studies have produced strong evidence that HD neuronal cells and especially those that make up the tissues that are first affected in the disease such as the striatum, are especially vulnerable to excitotoxic events and are characterized by aberrant synaptic and extra-synaptic functioning. HD model studies have shown that pre-symptomatic mice exhibit striatal dopamine signaling deficiencies and that dopamine receptor expression gradually declined with age, indicative of the potential role of the dopamine system in HD neuritic malformation and subsequent disease pathology [205,206]. The uptake of another important neurotransmitter, glutamate, has been also shown to be reduced in the prefrontal cortex of HD patients [207]. This reduction in glutamate uptake is usually also accompanied by a reduction in glutamate transporter 1 (*GLT1/EAAT2*) in corticostriatal regions [208,209]. The exact mechanism by which mutant huntingtin interferes with synaptic functioning and the deregulation of neurotransmitter levels is not fully understood yet. Nevertheless, HD model studies have shown that potential mecha-

nisms could include the Htt mutant fragment transcriptional deregulation of glutamate transporters that are mainly expressed by astrocytes that envelop synapses [210,211] and/or an inability to sustain the bioenergetics/glycolytic requirements for the proper functioning of the enzymes responsible for glutamate uptake reactions (GLT-1, GAP-DH). These enzymes in turn cause a neurotoxic release of glutamate to the extracellular medium [212,213]. Finally, other complementary studies that have provided clues to the potential mechanisms involved in such excitotoxic cell death have reported that: a) full length mutant huntingtin disturbs neuronal Ca^{2+} signaling and makes medium spiny neurons sensitive to glutamate-induced apoptotic events [214] b) anti-apoptotic and pro-apoptotic proteins such as the cell death regulator Bcl-2 and the transcription factor p53 are selectively deregulated in striatal neurons and make these neurons more vulnerable to excitotoxic cell death [215] c) changes in the levels or removal of BDNF or its tyrosine kinase receptor TrkB depletes the pro-survival signals that these molecules provide and inhibits striatal cellular functionality [216] and d) reductions in endocannabinoids and mutant Htt mediated disruption of their transcription which could in turn influence neurotransmitter release, synapse plasticity and the ability of striatal cells to respond to excitotoxicity challenges [217-219].

1.3.5 Autophagy

Increasing evidence points to the fact that the wild type Htt has a vital and active role in autophagy and is involved in autophagosome transport and biogenesis processes [220,221]. For this reason, several important clinical autophagy modulation clinical trials are under development that aim to enhance the ability of selective or general autophagic pathways to increase substrate recruitment, lysosomal activity and clear toxic proteins [222,223]. Autophagy is a cellular, protein clearance system that is divided into three main forms microautophagy, chaperone mediated autophagy and macroautophagy [224]. This classification serves to describe the way the cargo is transported to the lysosomes, and degraded by hydrolases. In macroautophagy the mechanism of toxic protein degradation involves autophagosome vesicle formation, its maturation and finally its fusion with the lysosomes [225,226]. In HD, it has been reported that the macroautophagic vacuoles are inefficient in engulfing their cytosolic loads and this in turn leads

to a reduction in their turnover, an increase in their total number in HD cells and can also be linked to the increased levels of protein aggregates and stored lipids [227]. Additionally, an important regulator of the macroautophagic process, the serine/threonine kinase mammalian target of rapamycin (mTOR) has also been reported to be inhibited and this inhibition has been attributed to the presence of the mutant Htt protein [228]. A separate study has also shown that the accumulation of mutant Htt can also stimulate the endosomal-lysosomal system and this in turn can lead to autophagic cell death [229]. Studies also support the notion that the expanded protein loses its ability to reversibly bind to the endoplasmic reticulum, the Golgi complex, maintain the wild type protein cellular localization properties and regulate stress induced autophagy [230-232] all of which have been associated with neuronal dysfunction and neuronal cell death in HD [233]. In chaperone mediate autophagy (CMA) the substrates are selectively chosen for destruction and delivered to the lysosomal membrane [234]. This is in contrast to the macroautophagy process where whole areas of the cytosol are engulfed and targeted to the lysosomes. In HD models, it has been shown that there is a compensatory regulatory mechanism where the CMA autophagic process activity is increased in response to a compromised macroautophagic pathway [235]. This increased activity is mediated through the upregulation of lysosome-associated protein type 2 a (LAMP-2A) and lysosomal HSC70 both of which proteins have been shown to be directly involved in the clearance of Htt [236]. However, with time the CMA autophagic pathway also gradually declines in its ability to compensate for the dysfunction of the macroautophagic system and as a result there is a generalized failure of autophagic clearance. In microautophagy the lysosomal membrane invaginates the material destined for destruction and internalized by the lysosomal lumen, however its molecular components are still not well understood in mammals [237,238].

1.4 Huntington's disease therapeutic strategies

1.4.1 Transcriptional activity restoration strategies

One of the potential methods to correct for the transcriptional deregulation observed in HD is through the inhibition of histone deacetylase activity. Histone deacetylase inhib-

itors such as phenylbutyrate and sodium butyrate have been previously used in an attempt to improve transcriptional dysfunction by the relaxation of DNA conformation, target HD specific pathological events such as caspase mediated cell death [239,240] or even improve HD phenotype through common neurological mechanisms such as improving neuronal BDNF trafficking [241]. In studies where histone deacetylase inhibition was used in HD models, it improved motor performance, appearance and body weight of the mouse models. It has been shown that deacetylase inhibition also reverses mutant huntingtin incited expression and causes a potentially beneficial change in the expression of a specific set of genes associated with the immune system and cell cycle – death, in the cerebellum, the cortex and the striatum of HD mice [242]. Apart from the inhibition of genome-wide transcriptional regulators such as histone deacetylase inhibitors, the transcriptional regulation of individual genes important for the HD has also been suggested as an alternative approach. Examples of such genes are the cAMP response element-binding (*CREB*) and CREB co-activator CBP, brain-derived neurotrophic factor, *REST* as well as the zinc finger transcription factor *SP1*. CREB signaling function has been shown to be reduced in HD and several studies have attempted to increase CREB levels in an effort to improve neuronal survival [243]. Giampa et al. showed that in a rat HD model phosphodiesterase type 10 inhibition increased CREB levels in spiny neurons and provided a neuroprotective effect [244]. Finally, in order to control pathological transcriptional deregulation, several compounds that affect transcription have been used such as anthracycline antibiotics [245]. Stack et al. showed that anthracycline administration in R6/2 HD mice improved nucleosome dynamics and the disease neurological phenotype, shifting the balance between histone methylation and acetylation, while Ryu et al. demonstrated that mithracyclin suppressed *SP1*, *SP3* related transcription in neurons through the suppression of the ESET (H3-K9) histone methyltransferase and increased HD mouse model survival rates [246,247].

1.4.2 Mutant huntingtin lowering strategies

Silencing of mutant huntingtin by RNA interference notably using siRNAs directed towards the mutant mRNA has become one of the most promising HD therapeutic trials [248]. By blocking the expression of the mutant protein the gain of function effects of

the mutant Htt can be potentially reversed [249]. However, in this strategy it is important to prevent the silencing of the wild type protein as well as other non-specific silencing events [250,251]. In this way, the beneficial effects of silencing can be maximized and patient safety is ensured by avoiding toxic side-effects of non-specific silencing, notably, of wild type Htt that has been associated with perinatal lethality and motor and cognitive defects in specific HD mouse models [252,253]. Even though the first attempts at silencing the mutant protein were performed using RNA interference (RNAi) technologies [254] subsequent studies showed that delivery and efficacy could be improved through the use of single stranded small inhibitory RNAs (siRNAs) and by using chemical modifications and design improvements of the administered molecules [255]. Moreover, additional experiments that have also shown great promise have been targeting the silencing of the mutant protein through the use of antisense oligonucleotides (AONs). The main difference between AONs and RNAi is that while AONs are delivered as single strand molecules RNAis are delivered as duplexes. Furthermore, RNAis are consequently engaged by the Argonaute protein family as the catalytic components of the RNA-induced silencing complex (RISC) lead only one of the two strands to eventually bind the complementary RNA [256]. Even though RNAi and AONs recognize their targets through Watson and Crick base pairing rules additional key differences that separate the two technologies are that compared to AONs RNAi works through a well-defined RNA degradative pathway (Drosha/Dicer), their targeting efficiency towards the mutant protein, the delivery efficiency to the targeted tissue and their half-life within the administered tissue cells [257,258]. Furthermore, since the silencing of wild type huntingtin function is undesirable due to its vital function in a plethora of cellular, neurological and neurodevelopmental processes [259] a lot of effort has been put into the allele selective silencing of the mutant protein, something that can be done through the targeting of single nucleotide polymorphisms [260,261]. Since the first silencing studies in which a significant reduction of mHtt was achieved through the administration of siRNA and anti-Htt constructs [262,263] a lot of preclinical HD model, Htt lowering studies have already been performed [264]. Some of the most recent, promising studies include those that incorporate the administration of cholesterol-conjugated Htt-siRNA in mice in order to increase tissue uptake [265], the allele specific knockdown of mHtt with S-constrained-ethyl (cET) motif AONs [266] and the AONs RNase-H-mediated

degradation of huntingtin through administration in HD mice cerebrospinal fluid [267].

1.4.3 Mutant huntingtin clearance and anti-aggregation strategies

In order to address the issue of the expanded mutant huntingtin resulting to a toxic gain of function a potential therapeutic strategy has been to identify modulators that possess anti-aggregational roles and that can lead to mutant protein aggregation and inclusion body reduction. A good example of experiments that attempt to reduce the accumulation of aggregated mutant proteins is through the use of chaperone protein member families. Chaperone proteins such as HSP40 and HSP70 have been known to promote refolding and degradation of misfolded proteins [268,269]. In a similar approach Labbadia and colleagues showed that induction of the heat shock response (HSR) via the heat shock factor 1 transcription factor (HSF1) and inhibition of chaperone HSP90 improved HD related phenotypes in the R6/2 mouse model [270]. A subsequent study from the same group and in HD transgenic mouse crossbreeds overexpressing the neuronal chaperone HSP1a (DNAJB2a) reduced mutant huntingtin aggregation and enhanced solubility [271]. Nonetheless, some of the above ameliorative effects, of the activation and overexpression of the chaperone machinery, have been transient and it has been suggested that synergistic combination therapies might be required for these therapeutic strategies to be more effective [272].

Other anti-aggregation approaches include those that use the administration of various, nontoxic, soluble disaccharides that act to stabilize the partially unfolded mutant huntingtin and prevent disease inclusion formation. One such compound, trehalose has been used in HD as well as other polyglutamine and neurodegenerative disease models and has shown to prevent neurodegeneration, enhance autophagy and alleviate disease mediated pathology [273-275]. Finally, much evidence suggests that cellular huntingtin clearance through induction of autophagy can also provide therapeutic benefits [276-279]. Apart from potential small molecule regulators of autophagy like trehalose and as described above, other approaches to regulate autophagic degradation of mutant huntingtin include: a) post-translational modifications of the mutant protein such phos-

phorylation of specific N-terminal serine residues [280,281] or acetylation of lysine 444 (K444) [282] b) autophagy induction through mTOR inhibition with rapamycin [283] or other mTOR dependent pathways and molecules [284,285] c) through other mTOR independent autophagy inducers such as L-type Ca²⁺ channel antagonists, K⁺ATP channel openers and other pharmacophores [286-288] .

1.4.4 Mitochondrial and synaptic function restoration strategies

Since mutant huntingtin has been shown to interfere with mitochondrial energy production and metabolism [289,290] it has been hypothesized that the administration of compounds and molecules that could replenish the energy cellular banks and improve the energy deficient profile in patients may also represent a likely therapeutic pathway. One of the molecules that has been proposed to have the potential to rectify the energy deficit in HD patients is creatine [291]. Creatine is synthesized in the kidney and the liver, taken up by tissues such as brain, heart and the skeletal muscle through a sodium dependent transporter [292] and together with phosphocreatine serve as short term energy banks when energetic demands rapidly increase [293]. Creatine has been shown to improve motor performance and reduce brain atrophy as well reverse mitochondrial dysfunction in transgenic mouse models of HD [294,295]. Additionally, a 16-week clinical trial of creatine administration showed that creatine was well tolerated and reduced oxidative stress levels in HD patients [296]. However even though creatine was also shown in a subsequent study [297] to improve cortical thinning, other aspects of the disease such as cognition were not affected. Therefore, considering the potential side effects of long term creatine administration, especially in presymptomatic individuals, further studies will be required to prove the applicability of this compound in HD. Another corresponding molecule, with neuroprotective and antioxidant properties, is the electron transport chain cofactor coenzyme q10 (CoQ10) which is involved in aerobic respiration and ATP energy production. CoQ10 has in some cases been combined with creatine administration to provide additional neuroprotection in HD as well as Parkinson's disease mouse models [298]. Multiple HD transgenic mouse models have demonstrated the neuroprotective properties of CoQ10 and shown that it can protect dopaminergic neurons, reduce

mitochondrial toxins as well as improve mouse model rotarod performance in combinatorial, preclinical trials [299,300]. It should be noted however that the results of clinical studies of coenzyme Q10 [301] have not been so promising as HD mouse model studies and considering the low treatment benefit compared to patient effort and energy requirement, further clinical trials of this molecule have been currently halted.

Along with mitochondrial restoration strategies much attention has been given to the restoration of cortico-striatal synaptic function in an effort to prevent selective vulnerability and neurodegeneration. The restoration of synaptic function has been the aim of many preclinical and clinical trials to regulate the release of neurotransmitters such as dopamine and glutamate, the functioning of neuroreceptors such as the N-methyl-D-aspartate receptor (NMDAR) and the expression levels and the release of neuromodulators and growth factors such as the endocannabinoids and brain derived neurotrophic factor [302]. In particular, experiments on transgenic R6/2 mouse models showed that dampening of the aberrant glutamate uptake by activation of metabotropic glutamate auto-receptors, resulted in increased model survival and a significant rescue in striatal and cortical neuronal loss [303]. Another attempt to prevent striatal loss and atrophy in HD as well as other neurodegenerative diseases has been through the overexpression of BDNF [304]. In HD, it has been shown that the increase of BDNF levels in YAC128 mouse models has resulted in the normalization of dopamine D2 receptor expression while striatal cell loss and motor dysfunction have also been reduced [305]. Finally, additional synaptic rescue schemes include the modulation of synaptic transmission via endocannabinoid signaling [306,307] and administration of neurotransmission inhibitory drugs as riluzole, memantine and the dopamine pathway inhibitor tetrabenzine [308-311].

1.4.5 Other strategies

Cell replacement therapy is another favorable approach that can potentially delay disease progression by replenishing the cells that have been lost due to the pathological effects of the mutant Htt protein. To date, cell therapy approaches have been through the use of stem cells, neural progenitor cells as well as fetal tissue cells [312]. El-Akabawy et al.

showed that the implantation of human neural stem cells in the R6/2 mouse model had suboptimal results due to low cell survival and differentiation. However, a different study by Rossignol et al. showed that co-transplantation of adult mesenchymal and neural stem cells in a transgenic rat model prolongs the survival of the neural stem cells and creates a more favorable transplantation microenvironment [313,314]. Transplantation of fetal striatal grafting has also been shown to improve the motor as well as the cognitive decline of HD patients. Nonetheless the grafts exhibited poor survival over time and conversely the grafting beneficial effects diminishing over time [315,316]. The poor survival of the grafts in the host has been attributed to poor vascularization. Trophic support can potentially be improved as grafting techniques and protocols are continuously improved [317,318]. Nevertheless, achieving the delicate balance of the type of stem cells to use (MSCs or iPSCs), during which HD disease stage (early, middle or late) and the specific neurodegeneration events these cells will target, are the greatest challenges of future stem cell trials and the determinant success factor for this therapeutic method [152].

To conclude the list of therapeutic approaches it has been suggested that targeting caspase dependent cleavage events is another prospective approach for the prevention of neuropathological features in HD and other neurodegenerative disorders [319]. According to the “toxic fragment hypothesis” the presence of multiple proteolytic sites on the Htt protein, in combination with the aberrant activity of proteases such as caspases and calpains may lead to numerous, variable length polyglutamine containing peptides that can be toxic. The identification of the specific combinations of enzymes and sites causing the most toxic peptides has been the focus of several research groups. Using YAC HD mouse models it has been shown that mice expressing mutant huntingtin resistant to caspase 6 cleavage, were protected against neurotoxic events and did not develop striatal neurodegeneration [320]. For this purpose, drugs like minocycline have been used in pre-clinical trials and in an attempt to inhibit the production of huntingtin toxic fragments by caspase cleavage [321,322]. Furthermore, initial clinical trials of minocycline use have exhibited stabilization of motor function and a significant amelioration of psychiatric symptoms in HD patients [323]. Even though the role of caspases is still not completely understood and the experimental results are not always consistent with the initial results from the caspase 6 resistant YAC mice [324], new molecules are constantly being

developed against caspase-6 aiming to increase the therapeutic potential of this method [325,326]. Yet increasing evidence points at important non-apoptotic roles of caspases such as caspase-6. Furthermore, alternative, complementary proteolytic pathways exist, which continue to give rise to the HD proteolytic toxic peptides (even after ablation or downregulation of caspase-6 function). This means that research in this direction should proceed with caution as to the molecules used and the extent to which the function of these proteases can and should be modified.

1.5 Biomarkers

1.5.1 What is a biomarker?

A biomarker is a physiological, molecular, biochemical or pharmacological measurement that can be obtained from the body of a patient and that can provide a good indication of disease prediction/progression or treatment efficacy in that patient [327]. Additionally, and according to the US Food and Drug administration (FDA) pharmacogenomics guidance (<http://www.fda.gov/drugs>) a biomarker should be measured in an analytical test system with clearly established performance characteristics and for which there is an established scientific framework that elucidates the significance of the biomarker test results. A good biomarker should also have the following properties: a) be able to detect disease features with high sensitivity (able to detect the condition when it is present) and high specificity (able to rule out a condition when it is absent), especially when compared to diseases with similar phenotypes and b) be easily, reliably and robustly detected, preferably in an easily collectable tissue (such as peripheral blood) and with minimum distress to the patient [328]. Finally, a good biomarker is judged by its positive predictive power (proportion of patients with a correct positive diagnosis over the total number of individuals who have been called to have the disease, true and false) and its negative predictive value (proportion of patients with a negative test and a correct diagnosis over the total number of people that have been called to not have the disease, including the false negatives).

Based on their disease specific properties and their relationship to disease, pathology




Figure.1 Biomarker type classification based on: a) the molecular subclass from which the identified biomarker originates b) biomarker tissue relative to disease central pathology tissue and c) biomarker provided information relative to disease risk (diagnostic), disease progression (prognostic), therapeutic potential (predictive) and safety or effectiveness of therapeutic approach.

biomarkers can be classified into: a) biomarkers which predict patient survival (prognostic), b) biomarkers which follow disease progression (monitoring biomarkers), c) biomarkers which can be used to evaluate drug safety and efficacy (pharmacodynamic), d) biomarkers which identify individuals likely to benefit from a treatment (predictive) and e) biomarkers which can predict the outcome given the response to therapy (surrogate biomarkers– see Figure 1) [329]. Prognostic and diagnostic biomarkers are grouped together and are otherwise called type 0 category biomarkers while therapeutic and surrogate biomarkers have been defined as type 1 and type 2 biomarkers respectively [330]. A prognostic biomarker can provide information about the outcome of the disease in

specific population groups however it cannot provide information about the patient's response to a treatment such as those provided by predictive biomarkers. On the other hand, pharmacodynamic markers can provide information about how well the treatment works (proof of principle) or can be used to optimize the dose of the administered treatment. Surrogate biomarkers are measurements that can potentially replace clinical endpoints and this is performed in a less labor intensive or expensive way than the standard and established clinical endpoint measurements methods for the specific disease. A biomarker can be an intrinsic measurement such as those provided by brain or other tissue imaging techniques, biomolecular and fluid sample tests or they can also be extrinsic. For example, an extrinsic surrogate biomarker can be cigarette smoking to the clinical end point of lung cancer. Moreover, biomarkers can be divided to the level to which they take place in a disease (molecule, cell etc.) or even according to their relationship to disease pathology (primary or secondary pathology) [331]. A good biomarker should also undergo validation and qualification [332]. Validation refers to the evaluation of the biomarker's sensitivity, specificity and reproducibility while on the other hand biomarker qualification refers to acquisition of the evidence linking a biomarker to a specific clinical endpoint [333]. Even though a biomarker can be linked, validated and qualified to a clinical endpoint (surrogate biomarker) this may not always be associated with disease causality [334]. Specifically, such a biomarker may be associated with the clinical endpoint but could nonetheless have nothing to do with the disease tissue pathology or the molecular pathways that lead to the disease specific endpoint. Such a biomarker could for example be a measurement in the peripheral blood of neurodegenerative disease patients not correlated to brain degeneration and its associated molecular pathways and yet correlated to specific disease endpoints. Finally, it should be emphasized that apart from the disease specific, drug and disease endpoint biomarker relationships, vital properties of a biomarker should be the detailed reporting of laboratory, experimental, clinical and statistical information that will allow for the unambiguous replication and reconstitution of the initial biomarker study results [330,335].

1.5.2 Biomarkers in Huntington's disease - needs and challenges

Different biomarkers can be developed for different clinical purposes. No diagnostic bio-

markers are needed for HD as diagnosis is done by the genetic identification of the number of CAG repeats. Thus, HD biomarker development is focusing on the areas of pharmacodynamics, therapeutic monitoring and disease progression diagnosis. Additionally, the ability to identify potential HD mutation carriers provides a period of several years to decades that can be used for presymptomatic therapeutic intervention. This is further emphasized by the fact that even though individuals exhibit no distinct phenotypic features during this preclinical, presymptomatic disease stage, subtle subclinical molecular and neurodegenerative events are already taking place [336-339]. Another reason that identification of good biomarkers is a top priority for HD research is the recent development of many potential treatments and therapeutic molecules (see 1.4). These therapeutic strategies have been partially validated with the help of various HD models. However, unless effective and standardized biomarkers have been described it will be very difficult to objectively describe any ameliorative outcomes of potential treatments when patients progress to the clinical trial stages. Such biomarkers should ideally describe the disease progression or even the pathology reversal equally well in early and presymptomatic patients, considering that these patients would benefit the most from therapeutic intervention. Nevertheless, even though high standards are required for the discovery of sensitive biomarkers, the multiplicity of pathological features in HD dictate that more than one type of biomarkers will be required to accurately describe the disease progression and the clinical trial benefits. Such a panel of biomarkers would be taking advantage of clinical progression tests, technological developments in imaging technologies and refinement of biochemical markers already under development. For Huntington's disease as well as other neuropsychiatric disorders, one of the main problems in studying the actual disease pathology is that it is hardly possible to collect tissue samples from brain areas of interest or obtain representative patient sample numbers to achieve the desired statistical power for a conclusive result [340,341]. Additionally, postmortem samples, which are sometimes also used to study the disease, are usually of suboptimal quality, either due to postmortem delay or due to pathological events affecting the tissue for several years, like in Huntington's disease [342-344]. Finally, development of qualified (see 1.5.1) and informative pharmacodynamic, monitoring and surrogate biomarkers will not only aid in the development of clinical trials and therapeutic agents but also assist researchers to get a better understanding of the disease pathology itself.

1.5.3 Blood based biomarkers for Huntington's disease

As described above HD patients are often irritable and exhibit choreatic symptoms and psychiatric disturbances (see 1.1.3/1.1.4). This makes it even more challenging to perform biopsies and secondary pathology tissue samplings and examinations in symptomatic patients. At the same time the ease with which peripheral blood can be collected repeatedly over a period of time, makes it a very attractive tissue for use in preclinical, clinical and biomarker discovery studies. Furthermore, huntingtin is also expressed in blood and, as such, surrogate biomarker changes could be identified in blood independently of potential causality to central disease pathology. The changes found in blood could reflect the effect of the mutant huntingtin itself within the tissue or secondary pathological events from other tissues, such as muscle. For example, it has been suggested that in neurodegenerative diseases the blood-brain barrier might be compromised, potentially exacerbating of brain pathology and causing leakage of proteins or other molecules [345]. Finally, profiling of gene expression in HD patients has shown that in whole blood and caudate samples transcription of large genomic regions is regulated in a synchronized fashion [346]. However, independently of the pathological mechanisms or other events traced by blood biomarkers they will need to be robustly associated with well-established HD clinical endpoints.

Blood consists mainly of plasma (55%), red blood cells (45%) and leukocytes and platelets (last two together ~ 1%). Most blood HD studies have been performed either using plasma and serum to examine the free proteins and molecules in these liquids; or using the leukocytes to examine cellular organization and disease related processes. The blood component or molecule under examination is often chosen based on the suspected deregulated disease pathway. By following one such hypothesis-driven approach and to study oxidative damage and dysfunction of the mitochondria in HD, serum levels of 8-hydroxy-2'-deoxyguanosine (8OH2'dG), an oxidative DNA damage indicator, have been investigated [296,347,348]. Its levels have been reported to be elevated in HD and other neurodegenerative diseases and HD mouse models overexpressing a hydrolase that break it down have conferred a protection against HD-like symptoms [349,350]. Additionally, its pharmacodynamic potential was tested by comparing its levels in HD

individuals before and after CoQ10 treatment [347] (for role of Coq10 in HD see 1.4.4). Nevertheless, the results have not always been consistent with the initial positive findings and it has been proposed that 8-hydroxy-2'-deoxyguanosine has only limited potential at assessing clinical disease features [351-353]. A more direct approach of disease specific biomarker identification involves the measurement of the mutant huntingtin itself in circulating T cells, B cells and monocytes [354,355]. The results of the study performed by Weiss et al. showed that mHtt leucocyte levels were lower in presymptomatic patients when compared to symptomatic and were also associated with disease burden and caudate atrophy scores. The quantification of mHtt itself as a biomarker obtained from peripheral readings such as blood or other peripheral fluids such as cerebrospinal fluid (CSF) can be very important since it can identify the effect of mutant protein lowering therapeutic strategies (pharmacodynamic) (see 1.4.2) ; can be indicative or associated with peripheral inflammation and immune system deregulations (see 1.2.4) (monitoring – predictive biomarker properties); and it can provide mechanistic links and clues to disease pathology. For example, the latter can be achieved by measuring mutant protein relationships in blood and other peripheral tissues, such as the relationship of soluble and aggregated mutant huntingtin levels [356]. Since it is not yet clear to which extent the interplay between aggregated and soluble mutant proteins forms influences neuronal cellular toxicity, the delineation of the relative amounts of the above two species or conformers can provide additional clues to the disease pathology and constitute on its own a type of biomarker. Other individual molecule and compound findings that have been described in HD blood include increased cytokine levels (mainly IL-6, IL-8 and TNF- α), kynurenine : tryptophan ratios as markers of microglial activation and persistent inflammation [357,358] and lower levels of BDNF, which is associated with striatal neuron survival signals, in HD patients serum and its association with longer CAG repeats [359].

Apart from specific hypothesis driven approaches, as illustrated above, peripheral blood has also been used in non-hypothesis driven efforts to identify peripheral biomarkers. Such non-hypothesis driven methodologies take advantage of state of the art high-throughput techniques such as mass spectrometry and genome wide gene expression profiling platforms to identify additional peripheral molecular biomarkers, among others metabolites and mRNAs [360,361]. To identify changes in mRNA expression levels in HD scientists

have mainly used whole peripheral blood and isolated leukocyte samples of patients as well as animal models [362-366]. Even though the overlap between studies result has not been very good for the mRNA changes identified, the per study findings have demonstrated that blood holds potential in being used as a source for disease progression and therapeutic efficacy. For example, Hu et.al. have demonstrated that dynamic regulator of chromatin plasticity H2A histone family (*H2AFY*) is overexpressed both in the blood and frontal cortex of HD patients, that this association precedes clinical symptoms and that the levels of this marker respond to a neurodegeneration suppressor, thus implying pharmacodynamic potential [364]. The above biomarker also contains many of the properties of an ideal biomarkers as it is validated in HD mouse models, changing according to disease severity and found early in the disease allowing for a wider therapeutic intervention window. Moreover, it has a known mechanism in disease pathology i.e. chromatin regulation (for the role of chromatin regulation in HD see 1.3.2) [367,368]. Apart from gene expression platforms metabolomics and proteomics technologies have been widely used to also identify such biomarkers in HD blood. Notably metabolomics could be a promising approach as deregulation of metabolism is a known HD pathology. Metabolomics and proteomics studies have also provided much information about the changes in patient blood samples [141,369-371]. For instance, proteomic and metabolomic changes in HD blood include altered levels of brain derived metabolites such as 24S-hydroxycholesterol in pre-manifest carriers, associated with metabolically active neuronal cells [372]; the presence of a catabolic phenotype in early HD patients, associated with aliphatic amino acids and changes in fatty acid breakdown markers like glycerol and malonate [373] and identification of neuroinflammation activation proteins in plasma [138]. Together all of the above results show that blood has great potential to provide prodromal, monitoring as well as pharmacodynamic HD biomarkers.

1.5.4 State of Huntington's disease clinical and imaging biomarkers

The identification of clinical biomarkers involves a series of tests and examinations that have the purpose of measuring cognitive and neuropsychiatric condition and motor function performance of mutation carriers. One of the best known of these tests

and the standard method of assessment of clinical disease progression is the Unified Huntington's Disease Rating Scale (UHDRS) [374]. This score comprises of different sub-scores that assess the patient's motor performance with tests such as oculomotor and finger tapping performance, tongue control and force, grip and posture control but also tests assessing their cognitive and functional condition. The advantages of such clinical measures are that they are usually inexpensive, standardized, relative quick and noninvasive. On the other hand, the disadvantages are that they are subjective and display inter and intra-rater variability [375]. However, despite potential disadvantages of some clinical markers there have been organized efforts such as the TRACK-HD and PREDICT-HD consortia that aim to improve the objectivity of these clinical measures as well as providing higher longitudinal change sensitivity and cross sectional differences in presymptomatic patients [376-380]. For example, 36-month observational data from the TRACK-HD study showed that several quantitative motor and cognitive tasks showed increased rates of decline. Furthermore, psychiatric markers such as apathy also exhibited significant increases [379] while the PREDICT-HD study reported that symptoms such as depression, anxiety and obsessive-compulsiveness were present more in HD mutation carriers [381].

A group of HD biomarkers that have produced some of the most significant results during the last years have been collected with the help of (neuro)imaging technologies. These technologies have the ability to describe brain loss changes as well as brain morphological changes in HD mutation carriers. The advantages of imaging techniques are that they non-invasive and that the data produced are in general well reproducible [382]. On the other hand, imaging techniques are usually quite expensive, especially when compared to clinical scoring systems. An additional disadvantage is that these examinations are sometimes difficult to perform due to the structural design of the imagers and the fact they can cause claustrophobia or are even unsuitable for patients that exhibit highly choreatic movements [376]. One of the most used of these technologies is magnetic resonance imaging. MRI studies have demonstrated how cortical degeneration is related to the clinical symptoms and how the cortical changes develop in different patients. One such prominent study by Rosas et al. showed that in HD subjects thinning of the cortical ribbons takes place from the posterior to anterior regions, that these changes take

place early in the disease and could be accountable for the disease heterogeneity [383]. In a subsequent study these patterns of cortical thinning were associated with different motor phenotypes, while functional and cognitive scores were closely related to specific cortical areas [384]. Other promising imaging techniques include functional MRI, PET, diffusor tensor imaging and magnetic resonance spectroscopy. These techniques can offer information about brain area dynamic changes, functional interconnectivity and microstructural degeneration [385,386]. Notably data from the IMAGE-HD study, using quantitative susceptibility mapping and multimodal magnetic resonance imaging, has shown that presymptomatic patient brain areas exhibited a higher iron content and that caudate volume loss could separate presymptomatic HD mutation carriers from controls respectively [387,388]. When it becomes possible to combine complementary information from different imaging types in longitudinal studies, this will greatly improve the potential and the sensitivity of imaging as a biomarker source. However, such an effort is not a small task and it will require greater standardization as well as the integration of different classes of professionals such as doctors, clinical researchers and statisticians [389].

1.5.5 Other molecular and biochemical fluid biomarkers

Aside from blood and the relative advantages it offers compared to other tissues, cerebrospinal fluid (CSF), muscle, saliva and urine have also provided useful and informative “wet” biomarkers for HD. The use of CSF is becoming increasingly popular in monitoring disease progression in other major neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease [369,390-392]. CSF advantages include the fact that it is also relatively accessible and that it interacts with central nervous system tissues and is “open” to brain derived proteins which can potentially mirror the pathological changes in the brain tissue. Wild et al. were able to reliably quantify mHtt at femtomolar sensitivity in mutation carriers’ CSF and also showed that higher mHtt load was correlated to reduced cognitive function and increased motor dysfunction in HD patients [393]. In a separate study, Tan et al. used postmortem samples to show that CSF possesses an mHtt and tissue specific property called cell-based aggregation (CBA) seeding, that seeds mutant huntingtin aggregation. This provides a mechanistic explanation for disease pa-

thology and can also act as a potential molecular biomarker for HD [394]. This CSF aggregate seeding propensity could be used to track disease progression (i.e. constituting a monitoring biomarker) by measuring CBA activity in a cell based assay. Saliva is another tissue that has been used to identify disease biomarkers, notably to study neuroendocrine regulation disturbances such as the hypothalamic-pituitary-adrenal (HPA) axis hyperactivity and depression found in HD carriers. Cortisol concentrations obtained from HD mutation carriers' saliva samples were increased, indicative of HPA axis dysfunction and also exhibited a correlation with motor and functional scores [395]. It should be noted however that the association of HPA axis activity with HD disease stages (pre-symptomatic vs (motor)symptomatic) and psychiatric symptoms (depression, suicidality) is not yet clear and further longitudinal studies are required for such saliva measurements to constitute potential biomarkers [396,397]. Additional examples of the use of other accessible fluids and tissues in biomarker identification include the reports of progressively increased cortisol levels in patient urine samples [398], the reduction of muscle contractility markers and a switch from fast to slow twitch muscle types in skeletal muscle of patients [399]. Finally, the function of the autonomic nervous system (ANS) in Huntington's disease has also been investigated to explore how this is affected in patients [400]. When standardized ANS system tests (sympathetic skin responses, blood pressure, heart rate variability etc.) were performed in patients, autonomic symptoms were found to be related to HD functional disability and depression and autonomic deregulation correlated with central nervous system degeneration tests and scores, such as the symbol digit modalities test and the UHDRS motor score [401,402]. These results support the notion that autonomic functional assessment could present a complementary non-invasive measure of disease progression.

Reference List

1. Huntington G: On chorea. George Huntington, M.D. *J Neuropsychiatry Clin Neurosci* 2003, 15: 109-112.
2. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE et al.: A polymorphic DNA marker genetically linked to Huntington's disease. *Nature* 1983, 306: 234-238.
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell* 1993, 72: 971-983.
4. MacDonald ME, Anderson MA, Gilliam TC, Tranejaerg L, Carpenter NJ, Magenis E et al.: A somatic cell hybrid panel for localizing DNA segments near the Huntington's disease gene. *Genomics* 1987, 1: 29-34.
5. Gilliam TC, Tanzi RE, Haines JL, Bonner TI, Faryniarz AG, Hobbs WJ et al.: Localization of the Huntington's disease gene to a small segment of chromosome 4 flanked by D4S10 and the telomere. *Cell* 1987, 50: 565-571.
6. Gusella JF, MacDonald ME: Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. *Nat Rev Neurosci* 2000, 1: 109-115.
7. Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL et al.: HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. *Eur J Hum Genet* 2011, 19: 561-566.
8. Walker FO: Huntington's disease. *Lancet* 2007, 369: 218-228.
9. Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L: Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. *J Neurol Neurosurg Psychiatry* 2013, 84: 1156-1160.
10. Conneally PM: Huntington disease: genetics and epidemiology. *Am J Hum Genet* 1984, 36: 506-526.
11. Novak MJ, Tabrizi SJ: Huntington's disease. *BMJ* 2010, 340: c3109.
12. Quarrell OW, Rigby AS, Barron L, Crow Y, Dalton A, Dennis N et al.: Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. *J Med Genet* 2007, 44: e68.
13. Myers RH: Huntington's disease genetics. *NeuroRx* 2004, 1: 255-262.

14. Williams AJ, Paulson HL: Polyglutamine neurodegeneration: protein misfolding revisited. *Trends Neurosci* 2008, 31: 521-528.
15. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M et al.: Trinucleotide repeat length instability and age of onset in Huntington's disease. *Nat Genet* 1993, 4: 387-392.
16. Ridley RM, Frith CD, Crow TJ, Conneally PM: Anticipation in Huntington's disease is inherited through the male line but may originate in the female. *J Med Genet* 1988, 25: 589-595.
17. Semaka A, Collins JA, Hayden MR: Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). *Am J Med Genet B Neuropsychiatr Genet* 2010, 153B: 314-320.
18. Gusella JF, MacDonald ME: Huntington's disease: the case for genetic modifiers. *Genome Med* 2009, 1: 80.
19. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S et al.: The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. *Nat Genet* 1993, 4: 398-403.
20. Gusella JF, MacDonald ME, Lee JM: Genetic modifiers of Huntington's disease. *Mov Disord* 2014, 29: 1359-1365.
21. Reiner A, Dragatsis I, Dietrich P: Genetics and neuropathology of Huntington's disease. *Int Rev Neurobiol* 2011, 98: 325-372.
22. Kovtun IV, Liu Y, Bjoras M, Klungland A, Wilson SH, McMurray CT: OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. *Nature* 2007, 447: 447-452.
23. Jonson I, Ougland R, Klungland A, Larsen E: Oxidative stress causes DNA triplet expansion in Huntington's disease mouse embryonic stem cells. *Stem Cell Res* 2013, 11: 1264-1271.
24. Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H et al.: CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. *Am J Hum Genet* 2009, 84: 351-366.
25. MacDonald ME, Vonsattel JP, Shrinidhi J, Couropmitree NN, Cupples LA, Bird ED et al.: Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. *Neurology* 1999, 53: 1330-1332.

26. Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT: NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. *Neurogenetics* 2005, 6: 25-28.
27. Chattopadhyay B, Baksi K, Mukhopadhyay S, Bhattacharyya NP: Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. *Neurosci Lett* 2005, 374: 81-86.
28. Weydt P, Soyak SM, Gellera C, Didonato S, Weidinger C, Oberkofler H et al.: The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. *Mol Neurodegener* 2009, 4: 3.
29. Taherzadeh-Fard E, Saft C, Andrich J, Wieczorek S, Arning L: PGC-1alpha as modifier of onset age in Huntington disease. *Mol Neurodegener* 2009, 4: 10.
30. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. *Cell* 2015, 162: 516-526.
31. Huntington G: On chorea. George Huntington, M.D. *J Neuropsychiatry Clin Neurosci* 2003, 15: 109-112.
32. Feigin A, Kiebertz K, Bordwell K, Como P, Steinberg K, Sotack J et al.: Functional decline in Huntington's disease. *Mov Disord* 1995, 10: 211-214.
33. Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M: Skeletal muscle pathology in Huntington's disease. *Front Physiol* 2014, 5: 380.
34. Kirkwood SC, Su JL, Conneally P, Foroud T: Progression of symptoms in the early and middle stages of Huntington disease. *Arch Neurol* 2001, 58: 273-278.
35. Lasker AG, Zee DS: Ocular motor abnormalities in Huntington's disease. *Vision Res* 1997, 37: 3639-3645.
36. Pierrot-Deseilligny C, Rivaud S, Gaymard B, Muri R, Vermersch AI: Cortical control of saccades. *Ann Neurol* 1995, 37: 557-567.
37. Patel SS, Jankovic J, Hood AJ, Jeter CB, Sereno AB: Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. *J Neurol Sci* 2012, 313: 35-41.
38. Heemskerk AW, Verbist BM, Marinus J, Heijnen B, Sjogren EV, Roos RA: The Huntington's Disease Dysphagia Scale. *Mov Disord* 2014, 29: 1312-1316.
39. Andrich JE, Wobben M, Klotz P, Goetze O, Saft C: Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain. *J Neural Transm (Vi-*

- enna) 2009, 116: 1607-1611.
40. Williams S, Heron L, France K, Mulrooney P, Edmondston SJ: Huntington's Disease: Characteristics of Fallers. *Physiother Res Int* 2014.
 41. Busse ME, Wiles CM, Rosser AE: Mobility and falls in people with Huntington's disease. *J Neurol Neurosurg Psychiatry* 2009, 80: 88-90.
 42. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL: Neuropsychiatric aspects of Huntington's disease. *J Neurol Neurosurg Psychiatry* 2001, 71: 310-314.
 43. Craufurd D, Thompson JC, Snowden JS: Behavioral changes in Huntington Disease. *Neuropsychiatry Neuropsychol Behav Neurol* 2001, 14: 219-226.
 44. Folstein S, Abbott MH, Chase GA, Jensen BA, Folstein MF: The association of affective disorder with Huntington's disease in a case series and in families. *Psychol Med* 1983, 13: 537-542.
 45. Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R et al.: Depression and stages of Huntington's disease. *J Neuropsychiatry Clin Neurosci* 2005, 17: 496-502.
 46. Alonso J, Ferrer M, Romera B, Vilagut G, Angermeyer M, Bernert S et al.: The European Study of the Epidemiology of Mental Disorders (ESEMeD/MHEDEA 2000) project: rationale and methods. *Int J Methods Psychiatr Res* 2002, 11: 55-67.
 47. Robins Wahlin TB: To know or not to know: a review of behaviour and suicidal ideation in preclinical Huntington's disease. *Patient Educ Couns* 2007, 65: 279-287.
 48. van der Meer LB, van DE, Giltay EJ, Tibben A: Do Attachment Style and Emotion Regulation Strategies Indicate Distress in Predictive Testing? *J Genet Couns* 2015, 24: 862-871.
 49. van DE, Kingma EM, van der Mast RC: Psychopathology in verified Huntington's disease gene carriers. *J Neuropsychiatry Clin Neurosci* 2007, 19: 441-448.
 50. Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J et al.: The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. *Epidemiol Psichiatr Soc* 2009, 18: 23-33.
 51. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH et al.: Apathy is not depression. *J Neuropsychiatry Clin Neurosci* 1998, 10: 314-319.
 52. Macdonald V, Halliday G: Pyramidal cell loss in motor cortices in Huntington's disease. *Neurobiol Dis* 2002, 10: 378-386.

53. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B et al.: Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. *Brain* 2008, 131: 1057-1068.
54. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB: Differential loss of striatal projection neurons in Huntington disease. *Proc Natl Acad Sci U S A* 1988, 85: 5733-5737.
55. Saudou F, Finkbeiner S, Devys D, Greenberg ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. *Cell* 1998, 95: 55-66.
56. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr.: Neuropathological classification of Huntington's disease. *J Neuropathol Exp Neurol* 1985, 44: 559-577.
57. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ: Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. *Neurology* 1994, 44: 823-828.
58. Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A et al.: Onset and rate of striatal atrophy in preclinical Huntington disease. *Neurology* 2004, 63: 66-72.
59. Glass M, Dragunow M, Faull RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. *Neuroscience* 2000, 97: 505-519.
60. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME et al.: Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. *Neurology* 2003, 60: 1615-1620.
61. Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E et al.: Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. *CNS Neurosci Ther* 2009, 15: 1-11.
62. Wild EJ, Henley SM, Hobbs NZ, Frost C, MacManus DG, Barker RA et al.: Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. *Mov Disord* 2010, 25: 888-895.

63. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B et al.: Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. *Brain* 2008, 131: 1057-1068.
64. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J et al.: Widespread expression of Huntington's disease gene (IT15) protein product. *Neuron* 1995, 14: 1065-1074.
65. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C et al.: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. *Neuron* 1995, 14: 1075-1081.
66. Gutekunst CA, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR et al.: Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. *Proc Natl Acad Sci U S A* 1995, 92: 8710-8714.
67. Gerber HP, Seipel K, Georgiev O, Hofferer M, Hug M, Rusconi S et al.: Transcriptional activation modulated by homopolymeric glutamine and proline stretches. *Science* 1994, 263: 808-811.
68. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ et al.: Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. *J Neurosci* 2008, 28: 10720-10733.
69. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A et al.: Huntingtin interacting proteins are genetic modifiers of neurodegeneration. *PLoS Genet* 2007, 3: e82.
70. Zuccato C, Valenza M, Cattaneo E: Molecular mechanisms and potential therapeutic targets in Huntington's disease. *Physiol Rev* 2010, 90: 905-981.
71. Tartari M, Gissi C, Lo S, V, Zuccato C, Picardi E, Pesole G et al.: Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. *Mol Biol Evol* 2008, 25: 330-338.
72. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK et al.: Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. *J Neurosci* 2002, 22: 7862-7872.
73. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE et al.: Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. *Cell Death Differ* 2004, 11: 424-438.

74. Xia J, Lee DH, Taylor J, Vandelft M, Truant R: Huntingtin contains a highly conserved nuclear export signal. *Hum Mol Genet* 2003, 12: 1393-1403.
75. Bhat KP, Yan S, Wang CE, Li S, Li XJ: Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A. *Proc Natl Acad Sci U S A* 2014, 111: 5706-5711.
76. Atkin G, Paulson H: Ubiquitin pathways in neurodegenerative disease. *Front Mol Neurosci* 2014, 7: 63.
77. Dong G, Callegari E, Gloeckner CJ, Ueffing M, Wang H: Mass spectrometric identification of novel posttranslational modification sites in Huntingtin. *Proteomics* 2012, 12: 2060-2064.
78. Havel LS, Wang CE, Wade B, Huang B, Li S, Li XJ: Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. *Hum Mol Genet* 2011, 20: 1424-1437.
79. Wang Y, Lin F, Qin ZH: The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease. *Neurosci Bull* 2010, 26: 153-162.
80. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C et al.: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. *Neuron* 1995, 14: 1075-1081.
81. Bhide PG, Day M, Sapp E, Schwarz C, Sheth A, Kim J et al.: Expression of normal and mutant huntingtin in the developing brain. *J Neurosci* 1996, 16: 5523-5535.
82. Hoogeveen AT, Willemsen R, Meyer N, de Rooij KE, Roos RA, van Ommen GJ et al.: Characterization and localization of the Huntington disease gene product. *Hum Mol Genet* 1993, 2: 2069-2073.
83. De Rooij KE, Dorsman JC, Smoor MA, Den Dunnen JT, Van Ommen GJ: Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. *Hum Mol Genet* 1996, 5: 1093-1099.
84. Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR et al.: Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. *J Neurosci* 2004, 24: 269-281.
85. Li SH, Li XJ: Huntingtin-protein interactions and the pathogenesis of Huntington's disease. *Trends Genet* 2004, 20: 146-154.

86. Gutekunst CA, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR et al.: Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. *Proc Natl Acad Sci U S A* 1995, 92: 8710-8714.
87. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J et al.: Huntingtin localization in brains of normal and Huntington's disease patients. *Ann Neurol* 1997, 42: 604-612.
88. Hoogeveen AT, Willemsen R, Meyer N, de Rooij KE, Roos RA, van Ommen GJ et al.: Characterization and localization of the Huntington disease gene product. *Hum Mol Genet* 1993, 2: 2069-2073.
89. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J et al.: Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. *Cell* 1995, 81: 811-823.
90. Reiner A, Dragatsis I, Zeitlin S, Goldowitz D: Wild-type huntingtin plays a role in brain development and neuronal survival. *Mol Neurobiol* 2003, 28: 259-276.
91. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C et al.: Wild-type huntingtin protects from apoptosis upstream of caspase-3. *J Neurosci* 2000, 20: 3705-3713.
92. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK et al.: Wild-type huntingtin protects neurons from excitotoxicity. *J Neurochem* 2006, 96: 1121-1129.
93. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L et al.: Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. *Science* 2001, 293: 493-498.
94. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP et al.: Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. *Cell* 2004, 118: 127-138.
95. Her LS, Goldstein LS: Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. *J Neurosci* 2008, 28: 13662-13672.
96. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B et al.: Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in *Drosophila*. *Neuron* 2003, 40: 25-40.
97. Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN et al.: Bidirectional

- control of postsynaptic density-95 (PSD-95) clustering by Huntingtin. *J Biol Chem* 2014, 289: 3518-3528.
98. Twelvetrees AE, Yuen EY, Arancibia-Carcamo IL, MacAskill AF, Rostaing P, Lumb MJ et al.: Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. *Neuron* 2010, 65: 53-65.
99. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP et al.: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* 1997, 277: 1990-1993.
100. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al.: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 1996, 87: 493-506.
101. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA et al.: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 1997, 90: 537-548.
102. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H et al.: The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. *Proc Natl Acad Sci U S A* 2000, 97: 6763-6768.
103. Donaldson KM, Li W, Ching KA, Batalov S, Tsai CC, Joazeiro CA: Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. *Proc Natl Acad Sci U S A* 2003, 100: 8892-8897.
104. Hickey MA, Chesselet MF: Apoptosis in Huntington's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 2003, 27: 255-265.
105. Damiano M, Galvan L, Deglon N, Brouillet E: Mitochondria in Huntington's disease. *Biochim Biophys Acta* 2010, 1802: 52-61.
106. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA: Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. *J Neurocytol* 2004, 33: 517-533.
107. Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, DiFiglia M et al.: Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. *J Biol Chem* 2010, 285: 14777-14790.
108. Arrasate M, Finkbeiner S: Protein aggregates in Huntington's disease. *Exp Neurol* 2012, 238: 1-11.

109. Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S: Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. *J Neurosci* 2010, 30: 10541-10550.
110. Colby DW, Cassady JP, Lin GC, Ingram VM, Wittrup KD: Stochastic kinetics of intracellular huntingtin aggregate formation. *Nat Chem Biol* 2006, 2: 319-323.
111. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K et al.: Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. *Nat Genet* 1998, 18: 150-154.
112. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE et al.: Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. *Cell Death Differ* 2004, 11: 424-438.
113. Bizat N, Hermel JM, Boyer F, Jacquard C, Creminon C, Ouary S et al.: Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. *J Neurosci* 2003, 23: 5020-5030.
114. Tam S, Spiess C, Auyeung W, Joachimiak L, Chen B, Poirier MA et al.: The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. *Nat Struct Mol Biol* 2009, 16: 1279-1285.
115. Kitamura A, Kubota H, Pack CG, Matsumoto G, Hirayama S, Takahashi Y et al.: Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. *Nat Cell Biol* 2006, 8: 1163-1170.
116. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, Simmons D et al.: Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. *J Biol Chem* 2009, 284: 29427-29436.
117. Wang Y, Lin F, Qin ZH: The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease. *Neurosci Bull* 2010, 26: 153-162.
118. Bates G: Huntingtin aggregation and toxicity in Huntington's disease. *Lancet* 2003, 361: 1642-1644.
119. Tagawa K, Hoshino M, Okuda T, Ueda H, Hayashi H, Engemann S et al.: Distinct aggregation and cell death patterns among different types of primary neurons induced by mutant huntingtin protein. *J Neurochem* 2004, 89: 974-987.

120. Jansen AH, van HM, Op den Kelder IC, Meier RT, de Ruiter AA, Schut MH et al.: Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. *Glia* 2016.
121. de la Monte SM, Vonsattel JP, Richardson EP, Jr.: Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. *J Neuropathol Exp Neurol* 1988, 47: 516-525.
122. Reading SA, Yassa MA, Bakker A, Dziorny AC, Gourley LM, Yallapragada V et al.: Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. *Psychiatry Res* 2005, 140: 55-62.
123. Kuppenbender KD, Standaert DG, Feuerstein TJ, Penney JB, Jr., Young AB, Landwehrmeyer GB: Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. *J Comp Neurol* 2000, 419: 407-421.
124. Joyce JN, Lexow N, Bird E, Winokur A: Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. *Synapse* 1988, 2: 546-557.
125. Tippet LJ, Waldvogel HJ, Thomas SJ, Hogg VM, van Roon-Mom W, Synek BJ et al.: Striosomes and mood dysfunction in Huntington's disease. *Brain* 2007, 130: 206-221.
126. Glass M, Dragunow M, Faull RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. *Neuroscience* 2000, 97: 505-519.
127. Cicchetti F, Prensa L, Wu Y, Parent A: Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. *Brain Res Brain Res Rev* 2000, 34: 80-101.
128. Waldvogel HJ, Kim EH, Tippet LJ, Vonsattel JP, Faull RL: The Neuropathology of Huntington's Disease. *Curr Top Behav Neurosci* 2015, 22: 33-80.
129. Selkoe DJ, Salazar FJ, Abraham C, Kosik KS: Huntington's disease: changes in striatal proteins reflect astrocytic gliosis. *Brain Res* 1982, 245: 117-125.
130. Reiner A, Del MN, Deng YP, Meade CA, Sun Z, Goldowitz D: R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric

- mice. *J Comp Neurol* 2007, 505: 603-629.
131. Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ: Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. *J Neurosci* 2003, 23: 2193-2202.
132. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA et al.: Microglial activation correlates with severity in Huntington disease: a clinical and PET study. *Neurology* 2006, 66: 1638-1643.
133. Politis M, Su P, Piccini P: Imaging of microglia in patients with neurodegenerative disorders. *Front Pharmacol* 2012, 3: 96.
134. van der Burg JM, Bjorkqvist M, Brundin P: Beyond the brain: widespread pathology in Huntington's disease. *Lancet Neurol* 2009, 8: 765-774.
135. Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersen A et al.: Testicular degeneration in Huntington disease. *Neurobiol Dis* 2007, 26: 512-520.
136. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J: Rate and correlates of weight change in Huntington's disease. *J Neurol Neurosurg Psychiatry* 2004, 75: 209-212.
137. Robbins AO, Ho AK, Barker RA: Weight changes in Huntington's disease. *Eur J Neurol* 2006, 13: e7.
138. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A et al.: Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. *J Proteome Res* 2007, 6: 2833-2840.
139. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N et al.: A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. *J Exp Med* 2008, 205: 1869-1877.
140. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F et al.: Formation of polyglutamine inclusions in non-CNS tissue. *Hum Mol Genet* 1999, 8: 813-822.
141. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N et al.: A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. *J Exp Med* 2008, 205: 1869-1877.
142. Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-

- Puig AJ et al.: The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. *Exp Neurol* 2008, 210: 691-698.
143. van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, Woodman B et al.: Increased metabolism in the R6/2 mouse model of Huntington's disease. *Neurobiol Dis* 2008, 29: 41-51.
144. Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C et al.: Gene expression in Huntington's disease skeletal muscle: a potential biomarker. *Hum Mol Genet* 2005, 14: 1863-1876.
145. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL et al.: Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. *Hum Mol Genet* 2002, 11: 1911-1926.
146. Bjorkqvist M, Fex M, Renstrom E, Wierup N, Petersen A, Gil J et al.: The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. *Hum Mol Genet* 2005, 14: 565-574.
147. Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA et al.: Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. *Neurobiol Dis* 2002, 11: 410-424.
148. Goodman AO, Barker RA: Body composition in premanifest Huntington's disease reveals lower bone density compared to controls. *PLoS Curr* 2011, 3: RRN1214.
149. Silvestroni A, Faull RL, Strand AD, Moller T: Distinct neuroinflammatory profile in post-mortem human Huntington's disease. *Neuroreport* 2009, 20: 1098-1103.
150. Ellrichmann G, Reick C, Saft C, Linker RA: The role of the immune system in Huntington's disease. *Clin Dev Immunol* 2013, 2013: 541259.
151. Crotti A, Glass CK: The choreography of neuroinflammation in Huntington's disease. *Trends Immunol* 2015, 36: 364-373.
152. Kwan W, Trager U, Davalos D, Chou A, Bouchard J, Andre R et al.: Mutant huntingtin impairs immune cell migration in Huntington disease. *J Clin Invest* 2012, 122: 4737-4747.
153. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM: Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. *FASEB J* 2001, 15: 1169-1180.

154. Meyer SU, Krebs S, Thirion C, Blum H, Krause S, Pfaffl MW: Tumor Necrosis Factor Alpha and Insulin-Like Growth Factor 1 Induced Modifications of the Gene Expression Kinetics of Differentiating Skeletal Muscle Cells. *PLoS One* 2015, 10: e0139520.
155. Li H, Li SH, Johnston H, Shelbourne PF, Li XJ: Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. *Nat Genet* 2000, 25: 385-389.
156. Li SH, Lam S, Cheng AL, Li XJ: Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. *Hum Mol Genet* 2000, 9: 2859-2867.
157. Wong BK, Ehrnhoefer DE, Graham RK, Martin DD, Ladha S, Uribe V et al.: Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. *Neurobiol Dis* 2015, 76: 24-36.
158. Cusack CL, Swahari V, Hampton HW, Michael RJ, Deshmukh M: Distinct pathways mediate axon degeneration during apoptosis and axon-specific pruning. *Nat Commun* 2013, 4: 1876.
159. Fonseca R, Vabulas RM, Hartl FU, Bonhoeffer T, Nagerl UV: A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP. *Neuron* 2006, 52: 239-245.
160. Wytenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J et al.: Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. *Proc Natl Acad Sci U S A* 2000, 97: 2898-2903.
161. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL: Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. *Mol Cell* 2004, 14: 95-104.
162. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI: Inefficient degradation of truncated polyglutamine proteins by the proteasome. *EMBO J* 2004, 23: 4307-4318.
163. Rousseau E, Kojima R, Hoffner G, Djian P, Bertolotti A: Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones. *J Biol Chem* 2009, 284: 1917-1929.
164. Diaz-Hernandez M, Valera AG, Moran MA, Gomez-Ramos P, Alvarez-Caste-

- lao B, Castano JG et al.: Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. *J Neurochem* 2006, 98: 1585-1596.
165. Schipper-Krom S, Juenemann K, Reits EA: The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue? *Biochem Res Int* 2012, 2012: 837015.
166. Harjes P, Wanker EE: The hunt for huntingtin function: interaction partners tell many different stories. *Trends Biochem Sci* 2003, 28: 425-433.
167. Marti E: RNA toxicity induced by expanded CAG repeats in Huntington's disease. *Brain Pathol* 2016.
168. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM et al.: Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. *Science* 2002, 296: 2238-2243.
169. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H et al.: The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. *Proc Natl Acad Sci U S A* 2000, 97: 6763-6768.
170. Obrietan K, Hoyt KR: CRE-mediated transcription is increased in Huntington's disease transgenic mice. *J Neurosci* 2004, 24: 791-796.
171. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM et al.: Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. *Science* 2002, 296: 2238-2243.
172. Moumne L, Betuing S, Caboche J: Multiple Aspects of Gene Dysregulation in Huntington's Disease. *Front Neurol* 2013, 4: 127.
173. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS et al.: Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. *Hum Mol Genet* 2000, 9: 1259-1271.
174. Labadorf A, Hoss AG, Lagomarsino V, Latourelle JC, Hadzi TC, Bregu J et al.: RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression. *PLoS One* 2015, 10: e0143563.
175. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G et al.: Regional and cellular gene expression changes in human Huntington's disease brain.

- Hum Mol Genet 2006, 15: 965-977.
176. Zuccato C, Belyaev N, Conforti P, Ooi L, Tartari M, Papadimou E et al.: Wide-spread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. *J Neurosci* 2007, 27: 6972-6983.
177. Chiang MC, Chen CM, Lee MR, Chen HW, Chen HM, Wu YS et al.: Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. *Hum Mol Genet* 2010, 19: 4043-4058.
178. Yamanaka T, Miyazaki H, Oyama F, Kurosawa M, Washizu C, Doi H et al.: Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. *EMBO J* 2008, 27: 827-839.
179. Gapp K, Woldemichael BT, Bohacek J, Mansuy IM: Epigenetic regulation in neurodevelopment and neurodegenerative diseases. *Neuroscience* 2014, 264: 99-111.
180. Lee J, Hwang YJ, Kim KY, Kowall NW, Ryu H: Epigenetic mechanisms of neurodegeneration in Huntington's disease. *Neurotherapeutics* 2013, 10: 664-676.
181. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in *Drosophila*. *Nature* 2001, 413: 739-743.
182. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B et al.: Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. *J Neurosci* 2003, 23: 9418-9427.
183. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA et al.: ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. *Proc Natl Acad Sci U S A* 2006, 103: 19176-19181.
184. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R et al.: Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. *Nat Med* 2002, 8: 143-149.
185. Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S et al.: A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. *Nucleic Acids Res* 2010, 38: 7219-

- 7235.
186. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL: The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. *J Neurosci* 2008, 28: 14341-14346.
 187. Seredenina T, Luthi-Carter R: What have we learned from gene expression profiles in Huntington's disease? *Neurobiol Dis* 2012, 45: 83-98.
 188. Chan DC: Mitochondria: dynamic organelles in disease, aging, and development. *Cell* 2006, 125: 1241-1252.
 189. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF, Jr. et al.: Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. *Nat Med* 1999, 5: 1194-1198.
 190. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ et al.: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci* 2002, 5: 731-736.
 191. Gellerich FN, Gizatullina Z, Nguyen HP, Trumbeckaite S, Vielhaber S, Seppet E et al.: Impaired regulation of brain mitochondria by extramitochondrial Ca²⁺ in transgenic Huntington disease rats. *J Biol Chem* 2008, 283: 30715-30724.
 192. Chang DT, Rintoul GL, Pandipati S, Reynolds IJ: Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. *Neurobiol Dis* 2006, 22: 388-400.
 193. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubinsztein DC: Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. *Hum Mol Genet* 2002, 11: 1137-1151.
 194. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. *Nat Rev Neurosci* 2007, 8: 57-69.
 195. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA et al.: Microglial activation correlates with severity in Huntington disease: a clinical and PET study. *Neurology* 2006, 66: 1638-1643.
 196. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH: Mitochondrial defect in Huntington's disease caudate nucleus. *Ann Neurol* 1996, 39: 385-389.

197. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J: Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. *Ann Neurol* 1982, 12: 425-434.
198. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M et al.: Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. *Brain* 1996, 119 (Pt 6): 2085-2095.
199. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D: Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. *Cell* 2006, 127: 59-69.
200. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR: Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. *Neurology* 1993, 43: 2689-2695.
201. Costa V, Scorrano L: Shaping the role of mitochondria in the pathogenesis of Huntington's disease. *EMBO J* 2012, 31: 1853-1864.
202. Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR et al.: Mutant huntingtin enhances excitotoxic cell death. *Mol Cell Neurosci* 2001, 17: 41-53.
203. Jakel RJ, Maragos WF: Neuronal cell death in Huntington's disease: a potential role for dopamine. *Trends Neurosci* 2000, 23: 239-245.
204. Polyzos AA, McMurray CT: The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease. *Mech Ageing Dev* 2016.
205. Cummings DM, Milnerwood AJ, Dallerac GM, Waights V, Brown JY, Vatsavayi SC et al.: Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. *Hum Mol Genet* 2006, 15: 2856-2868.
206. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A et al.: Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. *Proc Natl Acad Sci U S A* 2000, 97: 6809-6814.
207. Hassel B, Tessler S, Faull RL, Emson PC: Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. *Neurochem Res* 2008, 33: 232-237.
208. Estrada-Sanchez AM, Rebec GV: Corticostriatal dysfunction and glutamate

- transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes. *Basal Ganglia* 2012, 2: 57-66.
209. Miller BR, Dorner JL, Bunner KD, Gaither TW, Klein EL, Barton SJ et al.: Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease. *J Neurochem* 2012, 121: 629-638.
210. Lievens JC, Rival T, Iche M, Chneiweiss H, Birman S: Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in *Drosophila*. *Hum Mol Genet* 2005, 14: 713-724.
211. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB: Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. *Brain* 2002, 125: 1908-1922.
212. Estrada-Sanchez AM, Montiel T, Massieu L: Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice. *Neurochem Res* 2010, 35: 1156-1163.
213. Camacho A, Montiel T, Massieu L: The anion channel blocker, 4,4'-dinitrostilbene-2,2'-disulfonic acid prevents neuronal death and excitatory amino acid release during glycolysis inhibition in the hippocampus in vivo. *Neuroscience* 2006, 142: 1005-1017.
214. Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I: Full length mutant huntingtin is required for altered Ca^{2+} signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. *Neurobiol Dis* 2008, 31: 80-88.
215. Liang ZQ, Wang XX, Wang Y, Chuang DM, DiFiglia M, Chase TN et al.: Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. *Neurobiol Dis* 2005, 20: 562-573.
216. Li Y, Yui D, Luikart BW, McKay RM, Li Y, Rubenstein JL et al.: Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development. *Proc Natl Acad Sci U S A* 2012, 109: 15491-15496.
217. Van LK, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G et al.: Widespread decrease of type 1 cannabinoid receptor availability in Huntington dis-

- ease in vivo. *J Nucl Med* 2010, 51: 1413-1417.
218. Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR et al.: Down-regulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. *Eur J Neurosci* 2013, 37: 429-440.
219. Sepers MD, Raymond LA: Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. *Drug Discov Today* 2014, 19: 990-996.
220. Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR: Autophagy in Huntington disease and huntingtin in autophagy. *Trends Neurosci* 2015, 38: 26-35.
221. Rubinsztein DC, Codogno P, Levine B: Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat Rev Drug Discov* 2012, 11: 709-730.
222. Wild EJ, Tabrizi SJ: Targets for future clinical trials in Huntington's disease: what's in the pipeline? *Mov Disord* 2014, 29: 1434-1445.
223. Levine B, Packer M, Codogno P: Development of autophagy inducers in clinical medicine. *J Clin Invest* 2015, 125: 14-24.
224. Cortes CJ, La Spada AR: The many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapy. *Drug Discov Today* 2014, 19: 963-971.
225. Wong E, Cuervo AM: Autophagy gone awry in neurodegenerative diseases. *Nat Neurosci* 2010, 13: 805-811.
226. Nixon RA: The role of autophagy in neurodegenerative disease. *Nat Med* 2013, 19: 983-997.
227. Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S et al.: Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. *Nat Neurosci* 2010, 13: 567-576.
228. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC: Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. *Cell Death Differ* 2009, 16: 46-56.
229. Kegel KB, Kim M, Sapp E, McIntyre C, Castano JG, Aronin N et al.: Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. *J Neurosci* 2000, 20: 7268-7278.
230. Atwal RS, Truant R: A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of auto-

- phagy. *Autophagy* 2008, 4: 91-93.
231. Lee H, Noh JY, Oh Y, Kim Y, Chang JW, Chung CW et al.: IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux. *Hum Mol Genet* 2012, 21: 101-114.
 232. Reijonen S, Putkonen N, Norremolle A, Lindholm D, Korhonen L: Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. *Exp Cell Res* 2008, 314: 950-960.
 233. Vidal R, Caballero B, Couve A, Hetz C: Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. *Curr Mol Med* 2011, 11: 1-12.
 234. Cuervo AM: Chaperone-mediated autophagy: selectivity pays off. *Trends Endocrinol Metab* 2010, 21: 142-150.
 235. Koga H, Martinez-Vicente M, Arias E, Kaushik S, Sulzer D, Cuervo AM: Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease. *J Neurosci* 2011, 31: 18492-18505.
 236. Qi L, Zhang XD, Wu JC, Lin F, Wang J, DiFiglia M et al.: The role of chaperone-mediated autophagy in huntingtin degradation. *PLoS One* 2012, 7: e46834.
 237. Kaushik S, Singh R, Cuervo AM: Autophagic pathways and metabolic stress. *Diabetes Obes Metab* 2010, 12 Suppl 2: 4-14.
 238. Ahlberg J, Glaumann H: Uptake--microautophagy--and degradation of exogenous proteins by isolated rat liver lysosomes. Effects of pH, ATP, and inhibitors of proteolysis. *Exp Mol Pathol* 1985, 42: 78-88.
 239. Ferrante RJ, Kubitius JK, Lee J, Ryu H, Beesen A, Zucker B et al.: Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. *J Neurosci* 2003, 23: 9418-9427.
 240. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubitius JK et al.: Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. *J Biol Chem* 2005, 280: 556-563.
 241. Xu X, Kozikowski AP, Pozzo-Miller L: A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome. *Front Cell Neurosci* 2014, 8: 68.

242. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R et al.: The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. *Proc Natl Acad Sci U S A* 2008, 105: 15564-15569.
243. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF et al.: Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. *Hum Mol Genet* 2003, 12: 497-508.
244. Giampa C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G et al.: Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. *Neurobiol Dis* 2009, 34: 450-456.
245. Kumar A, Kumar SS, Kumar V, Kumar D, Agarwal S, Rana MK: Huntington's disease: an update of therapeutic strategies. *Gene* 2015, 556: 91-97.
246. Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S et al.: Modulation of nucleosome dynamics in Huntington's disease. *Hum Mol Genet* 2007, 16: 1164-1175.
247. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA et al.: ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. *Proc Natl Acad Sci U S A* 2006, 103: 19176-19181.
248. Choong CJ, Baba K, Mochizuki H: Gene therapy for neurological disorders. *Expert Opin Biol Ther* 2016, 16: 143-159.
249. Keiser MS, Kordasiewicz HB, McBride JL: Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. *Hum Mol Genet* 2016, 25: R53-R64.
250. Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, Alves S et al.: Sustained effects of nonallele-specific Huntingtin silencing. *Ann Neurol* 2009, 65: 276-285.
251. Zhang Y, Friedlander RM: Using non-coding small RNAs to develop therapies for Huntington's disease. *Gene Ther* 2011, 18: 1139-1149.
252. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL et al.: Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. *Nat Genet* 1997, 17: 404-410.
253. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J et al.: Targeted disruption of the Huntington's disease gene results in embryonic lethality

- and behavioral and morphological changes in heterozygotes. *Cell* 1995, 81: 811-823.
254. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al.: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. *Proc Natl Acad Sci U S A* 2005, 102: 5820-5825.
255. Yu D, Pendergraft H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE et al.: Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. *Cell* 2012, 150: 895-908.
256. Watts JK, Corey DR: Silencing disease genes in the laboratory and the clinic. *J Pathol* 2012, 226: 365-379.
257. Geary RS, Norris D, Yu R, Bennett CF: Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. *Adv Drug Deliv Rev* 2015, 87: 46-51.
258. McClorey G, Wood MJ: An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. *Curr Opin Pharmacol* 2015, 24: 52-58.
259. Dragatsis I, Levine MS, Zeitlin S: Inactivation of *Hdh* in the brain and testis results in progressive neurodegeneration and sterility in mice. *Nat Genet* 2000, 26: 300-306.
260. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M et al.: Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. *Curr Biol* 2009, 19: 774-778.
261. Evers MM, Toonen LJ, van Roon-Mom WM: Antisense oligonucleotides in therapy for neurodegenerative disorders. *Adv Drug Deliv Rev* 2015, 87: 90-103.
262. Chen ZJ, Kren BT, Wong PY, Low WC, Steer CJ: Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. *Biochem Biophys Res Commun* 2005, 329: 646-652.
263. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al.: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. *Proc Natl Acad Sci U S A* 2005, 102: 5820-5825.
264. Godinho BM, Malhotra M, O'Driscoll CM, Cryan JF: Delivering a disease-modifying treatment for Huntington's disease. *Drug Discov Today* 2015, 20: 50-64.
265. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M et al.: Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and corti-

- cal neuropathology and behavioral deficits. *Proc Natl Acad Sci U S A* 2007, 104: 17204-17209.
266. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N et al.: Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. *Mol Ther* 2011, 19: 2178-2185.
267. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA et al.: Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. *Neuron* 2012, 74: 1031-1044.
268. Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP et al.: Suppression of protein aggregation by chaperone modification of high molecular weight complexes. *Brain* 2012, 135: 1180-1196.
269. Kampinga HH, Craig EA: The HSP70 chaperone machinery: J proteins as drivers of functional specificity. *Nat Rev Mol Cell Biol* 2010, 11: 579-592.
270. Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T et al.: Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. *J Clin Invest* 2011, 121: 3306-3319.
271. Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP et al.: Suppression of protein aggregation by chaperone modification of high molecular weight complexes. *Brain* 2012, 135: 1180-1196.
272. Jackrel ME, Shorter J: Shock and awe: unleashing the heat shock response to treat Huntington disease. *J Clin Invest* 2011, 121: 2972-2975.
273. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H et al.: Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. *Nat Med* 2004, 10: 148-154.
274. Sarkar S, Rubinsztein DC: Small molecule enhancers of autophagy for neurodegenerative diseases. *Mol Biosyst* 2008, 4: 895-901.
275. Sarkar S, Rubinsztein DC: Huntington's disease: degradation of mutant huntingtin by autophagy. *FEBS J* 2008, 275: 4263-4270.
276. Lin F, Qin ZH: Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment? *J Huntingtons Dis* 2013, 2: 149-157.

- 277. Harris H, Rubinsztein DC: Control of autophagy as a therapy for neurodegenerative disease. *Nat Rev Neurol* 2012, 8: 108-117.
- 278. Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR: Autophagy in Huntington disease and huntingtin in autophagy. *Trends Neurosci* 2015, 38: 26-35.
- 279. Krainc D: Huntington's disease: tagged for clearance. *Nat Med* 2010, 16: 32-33.
- 280. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnaw A et al.: IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. *J Cell Biol* 2009, 187: 1083-1099.
- 281. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S et al.: Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. *Neuron* 2009, 64: 828-840.
- 282. Jeong H, Then F, Melia TJ, Jr., Mazzulli JR, Cui L, Savas JN et al.: Acetylation targets mutant huntingtin to autophagosomes for degradation. *Cell* 2009, 137: 60-72.
- 283. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG et al.: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 2004, 36: 585-595.
- 284. Ravikumar B, Stewart A, Kita H, Kato K, Duden R, Rubinsztein DC: Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. *Hum Mol Genet* 2003, 12: 985-994.
- 285. Lee JH, Tecedor L, Chen YH, Monteys AM, Sowada MJ, Thompson LM et al.: Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. *Neuron* 2015, 85: 303-315.
- 286. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC: Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. *Cell Death Differ* 2009, 16: 46-56.
- 287. Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S: A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. *Proc Natl Acad Sci U S A* 2010, 107: 16982-16987.
- 288. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH et al.: Novel

- targets for Huntington's disease in an mTOR-independent autophagy pathway. *Nat Chem Biol* 2008, 4: 295-305.
289. Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL et al.: Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. *Hum Mol Genet* 2012, 21: 406-420.
290. Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ et al.: The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. *Exp Neurol* 2008, 210: 691-698.
291. Beal MF: Neuroprotective effects of creatine. *Amino Acids* 2011, 40: 1305-1313.
292. Sora I, Richman J, Santoro G, Wei H, Wang Y, Vanderah T et al.: The cloning and expression of a human creatine transporter. *Biochem Biophys Res Commun* 1994, 204: 419-427.
293. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM: Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. *Biochem J* 1992, 281 (Pt 1): 21-40.
294. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK et al.: Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. *J Neurosci* 2000, 20: 4389-4397.
295. Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF et al.: Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. *J Neurochem* 2003, 85: 1359-1367.
296. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M et al.: Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. *Neurology* 2006, 66: 250-252.
297. Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP et al.: PRE-CREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. *Neurology* 2014, 82: 850-857.
298. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ et al.: Combination therapy with coenzyme Q10 and creatine produces additive neuro-

- protective effects in models of Parkinson's and Huntington's diseases. *J Neurochem* 2009, 109: 1427-1439.
299. Beal MF, Matthews RT, Tieleman A, Shults CW: Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. *Brain Res* 1998, 783: 109-114.
300. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW et al.: Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. *Biochim Biophys Acta* 2006, 1762: 373-380.
301. Hyson HC, Kiebertz K, Shoulson I, McDermott M, Ravina B, de Bleeck EA et al.: Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. *Mov Disord* 2010, 25: 1924-1928.
302. Sepers MD, Raymond LA: Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. *Drug Discov Today* 2014, 19: 990-996.
303. Reiner A, Lafferty DC, Wang HB, Del MN, Deng YP: The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice. *Neurobiol Dis* 2012, 47: 75-91.
304. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P: BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. *Nat Rev Neurosci* 2013, 14: 401-416.
305. Xie Y, Hayden MR, Xu B: BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. *J Neurosci* 2010, 30: 14708-14718.
306. Navarrete M, Araque A: Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. *Neuron* 2010, 68: 113-126.
307. Micale V, Di M, V, Sulcova A, Wotjak CT, Drago F: Endocannabinoid system and mood disorders: priming a target for new therapies. *Pharmacol Ther* 2013, 138: 18-37.
308. Schiefer J, Landwehrmeyer GB, Luesse HG, Sprunken A, Puls C, Milkereit A et al.: Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. *Mov Disord* 2002, 17: 748-757.
309. Landwehrmeyer GB, Dubois B, de Yebenes JG, Kremer B, Gaus W, Kraus PH et al.: Riluzole in Huntington's disease: a 3-year, randomized controlled study. *Ann*

- Neurol 2007, 62: 262-272.
310. Lee ST, Chu K, Park JE, Kang L, Ko SY, Jung KH et al.: Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. *Brain Res* 2006, 1118: 199-207.
311. Huntington Study Group: Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. *Neurology* 2006, 66: 366-372.
312. Chen Y, Carter RL, Cho IK, Chan AW: Cell-based therapies for Huntington's disease. *Drug Discov Today* 2014, 19: 980-984.
313. Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J et al.: Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease. *Stem Cells* 2014, 32: 500-509.
314. El-Akabawy G, Rattray I, Johansson SM, Gale R, Bates G, Modo M: Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease. *BMC Neurosci* 2012, 13: 97.
315. Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M et al.: Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. *Brain* 2013, 136: 433-443.
316. Paganini M, Biggeri A, Romoli AM, Mechi C, Ghelli E, Berti V et al.: Fetal striatal grafting slows motor and cognitive decline of Huntington's disease. *J Neurol Neurosurg Psychiatry* 2014, 85: 974-981.
317. Gallina P, Paganini M, Biggeri A, Marini M, Romoli A, Sarchielli E et al.: Human striatum remodelling after neurotransplantation in Huntington's disease. *Stereotact Funct Neurosurg* 2014, 92: 211-217.
318. Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P et al.: Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. *Lancet Neurol* 2006, 5: 303-309.
319. Wang XJ, Cao Q, Zhang Y, Su XD: Activation and regulation of caspase-6 and its role in neurodegenerative diseases. *Annu Rev Pharmacol Toxicol* 2015, 55: 553-572.
320. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G et al.: Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant

- huntingtin. *Cell* 2006, 125: 1179-1191.
321. Hersch S, Fink K, Vonsattel JP, Friedlander RM: Minocycline is protective in a mouse model of Huntington's disease. *Ann Neurol* 2003, 54: 841-843.
322. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E et al.: Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. *Proc Natl Acad Sci U S A* 2003, 100: 10483-10487.
323. Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP: Neuroprotection in Huntington's disease: a 2-year study on minocycline. *Int Clin Psychopharmacol* 2004, 19: 337-342.
324. Landles C, Weiss A, Franklin S, Howland D, Bates G: Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease. *PLoS Curr* 2012, 4: e4fd085bfc9973.
325. Varma H, Voisine C, DeMarco CT, Cattaneo E, Lo DC, Hart AC et al.: Selective inhibitors of death in mutant huntingtin cells. *Nat Chem Biol* 2007, 3: 99-100.
326. Chu W, Rothfuss J, Chu Y, Zhou D, Mach RH: Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. *J Med Chem* 2009, 52: 2188-2191.
327. Dunckley T, Coon KD, Stephan DA: Discovery and development of biomarkers of neurological disease. *Drug Discov Today* 2005, 10: 326-334.
328. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001, 69: 89-95.
329. de GA, Watson S, Ellis LM, Rodon J, Tabernero J, de GA et al.: Pragmatic issues in biomarker evaluation for targeted therapies in cancer. *Nat Rev Clin Oncol* 2015, 12: 197-212.
330. Azuaje F, Devaux Y, Wagner D: Challenges and standards in reporting diagnostic and prognostic biomarker studies. *Clin Transl Sci* 2009, 2: 156-161.
331. Aronson JK: Research priorities in biomarkers and surrogate end-points. *Br J Clin Pharmacol* 2012, 73: 900-907.
332. Chau CH, Rixe O, McLeod H, Figg WD: Validation of analytic methods for biomarkers used in drug development. *Clin Cancer Res* 2008, 14: 5967-5976.
333. Wagner JA: Overview of biomarkers and surrogate endpoints in drug develop-

- ment. *Dis Markers* 2002, 18: 41-46.
334. Strimbu K, Tavel JA: What are biomarkers? *Curr Opin HIV AIDS* 2010, 5: 463-466.
335. Beam CA: Statistical considerations when analyzing biomarker data. *Clin Immunol* 2015, 161: 31-36.
336. Siemers E, Foroud T, Bill DJ, Sorbel J, Norton JA, Jr., Hodes ME et al.: Motor changes in presymptomatic Huntington disease gene carriers. *Arch Neurol* 1996, 53: 487-492.
337. Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V et al.: Functional brain changes in presymptomatic Huntington's disease. *Ann Neurol* 2004, 55: 879-883.
338. Harrington DL, Rubinov M, Durgerian S, Mourany L, Reece C, Koenig K et al.: Network topology and functional connectivity disturbances precede the onset of Huntington's disease. *Brain* 2015, 138: 2332-2346.
339. Morris JC, Price JL: Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. *J Mol Neurosci* 2001, 17: 101-118.
340. Warren JD, Schott JM, Fox NC, Thom M, Revesz T, Holton JL et al.: Brain biopsy in dementia. *Brain* 2005, 128: 2016-2025.
341. Schott JM, Reiniger L, Thom M, Holton JL, Grieve J, Brandner S et al.: Brain biopsy in dementia: clinical indications and diagnostic approach. *Acta Neuropathol* 2010, 120: 327-341.
342. Ravid R, Van Zwieten EJ, Swaab DF: Brain banking and the human hypothalamus--factors to match for, pitfalls and potentials. *Prog Brain Res* 1992, 93: 83-95.
343. Webster MJ: Tissue preparation and banking. *Prog Brain Res* 2006, 158: 3-14.
344. Hynd MR, Lewohl JM, Scott HL, Dodd PR: Biochemical and molecular studies using human autopsy brain tissue. *J Neurochem* 2003, 85: 543-562.
345. Carvey PM, Hendey B, Monahan AJ: The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. *J Neurochem* 2009, 111: 291-314.
346. Anderson AN, Roncaroli F, Hodges A, Deprez M, Turkheimer FE: Chromosomal profiles of gene expression in Huntington's disease. *Brain* 2008, 131: 381-388.
347. Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I et al.: Plas-

- ma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10. *J Huntingtons Dis* 2012, 1: 65-69.
348. Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS: 8OHdG as a marker for Huntington disease progression. *Neurobiol Dis* 2012, 46: 625-634.
349. Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H et al.: Increased oxidative damage to DNA in ALS patients. *Free Radic Biol Med* 2000, 29: 652-658.
350. De LG, Russo MT, Degan P, Tiveron C, Zijno A, Meccia E et al.: A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration. *PLoS Genet* 2008, 4: e1000266.
351. Ciancarelli I, De AD, Di MC, Di SC, Pistarini C, D'Orazio N et al.: Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington's patients. *Biomarkers* 2014, 19: 452-456.
352. Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A et al.: 8OHdG is not a biomarker for Huntington disease state or progression. *Neurology* 2013, 80: 1934-1941.
353. Killoran A, Biglan KM: 8-OHdG: its (limited) potential as a biomarker for Huntington's disease. *Biomark Med* 2012, 6: 777-780.
354. Massai L, Petricca L, Magnoni L, Rovetini L, Haider S, Andre R et al.: Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells. *BMC Biochem* 2013, 14: 34.
355. Weiss A, Trager U, Wild EJ, Grueninger S, Farmer R, Landles C et al.: Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. *J Clin Invest* 2012, 122: 3731-3736.
356. Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC et al.: TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. *Chem Biol* 2012, 19: 264-275.
357. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW et al.: Tryptophan metabolism and oxidative stress in patients with Huntington's disease. *J Neurochem* 2005, 93: 611-623.
358. Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P et al.: Increased central microglial activation associated with peripheral cytokine levels in premanifest

- Huntington's disease gene carriers. *Neurobiol Dis* 2015, 83: 115-121.
359. Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L et al.: Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. *Am J Med Genet B Neuropsychiatr Genet* 2007, 144B: 574-577.
360. Seredenina T, Luthi-Carter R: What have we learned from gene expression profiles in Huntington's disease? *Neurobiol Dis* 2012, 45: 83-98.
361. Botas A, Campbell HM, Han X, Maletic-Savatic M: Metabolomics of neurodegenerative diseases. *Int Rev Neurobiol* 2015, 122: 53-80.
362. Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD et al.: Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. *Proc Natl Acad Sci U S A* 2007, 104: 14424-14429.
363. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD et al.: Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. *Proc Natl Acad Sci U S A* 2005, 102: 11023-11028.
364. Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H et al.: Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. *Proc Natl Acad Sci U S A* 2011, 108: 17141-17146.
365. Chang KH, Chen YC, Wu YR, Lee WF, Chen CM: Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients. *PLoS One* 2012, 7: e46492.
366. Kocerha J, Liu Y, Willoughby D, Chidamparam K, Benito J, Nelson K et al.: Longitudinal transcriptomic dysregulation in the peripheral blood of transgenic Huntington's disease monkeys. *BMC Neurosci* 2013, 14: 88.
367. Reilmann R: Does chromatin modulation provide the first wet biomarker for Huntington's disease? *Mov Disord* 2012, 27: 473.
368. Ehrlich ME, Gandy S: Chromatin plasticity and the pathogenesis of Huntington disease. *Proc Natl Acad Sci U S A* 2011, 108: 16867-16868.
369. Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K et al.: Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. *Biochim Biophys Acta* 2010, 1802: 673-681.
370. Chang KH, Wu YR, Chen YC, Chen CM: Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. *Brain Behav Immun* 2015, 44:

- 121-127.
371. Silajdzic E, Rezeli M, Vegvari A, Lahiri N, Andre R, Magnusson-Lind A et al.: A critical evaluation of inflammatory markers in Huntington's Disease plasma. *J Huntingtons Dis* 2013, 2: 125-134.
372. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM et al.: Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. *Brain* 2008, 131: 2851-2859.
373. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C et al.: Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. *Brain* 2006, 129: 877-886.
374. Shoulson I, Fahn S: Huntington disease: clinical care and evaluation. *Neurology* 1979, 29: 1-3.
375. Henley SM, Bates GP, Tabrizi SJ: Biomarkers for neurodegenerative diseases. *Curr Opin Neurol* 2005, 18: 698-705.
376. Andre R, Scahill RI, Haider S, Tabrizi SJ: Biomarker development for Huntington's disease. *Drug Discov Today* 2014, 19: 972-979.
377. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D et al.: Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurol* 2009, 8: 791-801.
378. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R et al.: Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *Lancet Neurol* 2011, 10: 31-42.
379. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA et al.: Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *Lancet Neurol* 2013, 12: 637-649.
380. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M et al.: Detection of Huntington's disease decades before diagnosis: the Predict-HD study. *J Neurol Neurosurg Psychiatry* 2008, 79: 874-880.
381. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC: Psychiatric symp-

- toms in Huntington's disease before diagnosis: the predict-HD study. *Biol Psychiatry* 2007, 62: 1341-1346.
382. Weir DW, Sturrock A, Leavitt BR: Development of biomarkers for Huntington's disease. *Lancet Neurol* 2011, 10: 573-590.
383. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH et al.: Regional and progressive thinning of the cortical ribbon in Huntington's disease. *Neurology* 2002, 58: 695-701.
384. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B et al.: Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. *Brain* 2008, 131: 1057-1068.
385. Georgiou-Karistianis N: A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle? *Exp Neurol* 2009, 220: 5-8.
386. Poudel GR, Stout JC, Dominguez DJ, Churchyard A, Chua P, Egan GF et al.: Longitudinal change in white matter microstructure in Huntington's disease: The IMAGE-HD study. *Neurobiol Dis* 2015, 74: 406-412.
387. Dominguez DJ, Ng AC, Poudel G, Stout JC, Churchyard A, Chua P et al.: Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study. *J Neurol Neurosurg Psychiatry* 2016, 87: 545-549.
388. JF D, Stout JC, Poudel G, Churchyard A, Chua P, Egan GF et al.: Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data. *Br J Psychiatry* 2016, 208: 571-578.
389. Puopolo M, Pocchiari M: Need to improve clinical trials in rare neurodegenerative disorders. *Ann Ist Super Sanita* 2011, 47: 55-59.
390. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al.: Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. *JAMA Neurol* 2013, 70: 1277-1287.
391. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG: alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. *Lancet Neurol* 2011, 10: 230-240.
392. Blennow K, Zetterberg H, Fagan AM: Fluid biomarkers in Alzheimer disease.

- Cold Spring Harb Perspect Med 2012, 2: a006221.
393. Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR et al.: Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. *J Clin Invest* 2015, 125: 1979-1986.
394. Tan Z, Dai W, van Erp TG, Overman J, Demuro A, Digman MA et al.: Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin. *Mol Psychiatry* 2015, 20: 1286-1293.
395. Aziz NA, Pijl H, Frolich M, van der Graaf AW, Roelfsema F, Roos RA: Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. *J Clin Endocrinol Metab* 2009, 94: 1223-1228.
396. Shirbin CA, Chua P, Churchyard A, Lowndes G, Hannan AJ, Pang TY et al.: Cortisol and depression in pre-diagnosed and early stage Huntington's disease. *Psychoneuroendocrinology* 2013, 38: 2439-2447.
397. Hubers AA, van der Mast RC, Pereira AM, Roos RA, Veen LJ, Cobbaert CM et al.: Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease and its association with depressive symptoms and suicidality. *J Neuroendocrinol* 2015, 27: 234-244.
398. Bjorkqvist M, Petersen A, Bacos K, Isaacs J, Norlen P, Gil J et al.: Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. *Hum Mol Genet* 2006, 15: 1713-1721.
399. Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C et al.: Gene expression in Huntington's disease skeletal muscle: a potential biomarker. *Hum Mol Genet* 2005, 14: 1863-1876.
400. Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT et al.: Autonomic nervous system function in Huntington's disease. *J Neurol Neurosurg Psychiatry* 2002, 72: 726-731.
401. Kobal J, Melik Z, Cankar K, Strucl M: Cognitive and autonomic dysfunction in presymptomatic and early Huntington's disease. *J Neurol* 2014, 261: 1119-1125.
402. Aziz NA, Anguelova GV, Marinus J, van Dijk JG, Roos RA: Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. *Eur J Neurol* 2010, 17: 1068-1074.